Ionizable sterol derivative for delivering therapeutic agent and use thereof

HK40137267APending Publication Date: 2026-09-11BEIJING INNO MEDICINE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK42026125309
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-09-18
Filing Date
2026-06-25
Publication Date
2026-09-11

Smart Images

  • Figure 00000054_0000
    Figure 00000054_0000
  • Figure 00000054_0001
    Figure 00000054_0001
  • Figure 00000055_0000
    Figure 00000055_0000
Patent Text Reader

Abstract

The present disclosure relates to ionizable sterol compounds of Formula A, lipid nanoparticle compositions comprising the same, and medical uses thereof. And Z-L-(M) r A.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202511325987.9 (22) Application Date 2025.09.17 (66) Domestic Priority Data 202411302863.4 2024.09.18 CN (71) Applicant Beijing Yinno Pharmaceutical Technology Co., Ltd. Address 101-301, 3rd Floor, Building 9, Zone 4, Xishan Creative Park, Haidian District, Beijing 100195 (72) Inventors Ma Qian, Sun Jiefang (74) Patent Agency Beijing Zhongzi Law Firm 11247 Patent Attorneys Chen Runjie, Huang Gesheng (51) Int.Cl. C07J 43 / 00 (2006.01) A61K 31 / 7088 (2006.01) A61K 47 / 28 (2006.01) A61K 9 / 51(2006.01) A61K 48 / 00(2006.01) A61P 31 / 00(2006.01) A61P 35 / 00(2006.01) A61P 37 / 02(2006.01) A61P 3 / 10(2006.01) A61P 25 / 28(2006.01) A61P 9 / 00(2006.01) A61P 13 / 12(2006.01) A61P 9 / 14(2006.01) A61P 3 / 00(2006.01) (54) Invention Title: Ionizable Sterol Derivatives for Delivery of Therapeutic Agents and Their Uses (57) Abstract: This disclosure relates to ionizable sterol compounds of formula A, lipid nanoparticle compositions comprising the same, and their pharmaceutical uses. Z-L-(M)r A. Claims 12 pages, Description 41 pages, Drawings 5 ​​pages, CN 121378377 A 2026.01.23 CN 1 21 37 83 77 A 1. An ionizable sterol compound of formula A, or a stereoisomer thereof, a pharmaceutically acceptable salt or solvate thereof, Z-L-(M)r of formula A, wherein: Z is the structure described in formula B below, wherein the wavy line indicates the connection point with L; R1a is H, C1-6 alkyl, -C(O)NRaRb, -C(O)Rc, -C(O)ORd, or an amino acid residue wherein Re is selected from the residue portion of L-histidine, L-leucine, L-isoleucine, L-valine, L-phenylalanine, L-tryptophan, L-lysine, L-tyrosine; Ra and Rb may be the same as or different from each other, and are selected from H, -C1-6 alkyl, -C2-6 alkenyl, and -C2-6 ynyl, each optionally substituted by one or more groups selected from allyl, carbonyl, and 5- to 10-membered heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S.Rc and Rd are each independently -C1-6 alkyl, -C2-6 alkenyl, or -C2-6 alkynyl; R1b is H, -C1-6 alkyl, -C2-6 alkenyl, or -C2-6 alkynyl; R2 is H, OH, or -OC1-6 alkyl; R3 is H or CH3; when W is a single bond with the carbon atom at the adjacent * position, W is selected from N and CRf, and R4 is H or OH; when W is a double bond with the carbon atom at the adjacent * position, W is C, and R4 is absent; Rf is absent, H, halogen, or -C1-6 alkyl; R5a and R5b are each independently H, OH, or -OC1-6 alkyl, or R5a and R5b together with the ring carbon atoms they are attached to form -C(O)-. L is a linker unit, which is a linear or branched alkylene group with optional substitutions having 3-50 skeletal carbon atoms, covalently linked to a steroidal ring segment and r ionizable head groups M, wherein at least one skeletal carbon atom of L is replaced by -O-, -S-, -NR6-, -NR6-NR6', -N=N-, -CH=N-, -N=CH-, -CH=CH-, -C≡C-, -O-NR6, -S-S-, -SO-, -SO2, -C(O)-, -C(=S)-, -C(=NR6)-, -C(O)O-, -C(O)S-, -OC(O)-, -SC(O)-, -NR6C(O)-, -C(O)NR6-, - NR6SO2-、-SO2NR6-、-OC(O)O-、-NR6C(O)O-、-OC(O)NR6-、-SC(O)NR6-、-NR6C(O)NR6'-、-NR6C (O)S-、-P(O)(OR6)O-、-OP(O)(OR6)-、-OP(O)(OR6)O-、Optionally substituted C3-8 cycloalkylene, Optionally substituted 3-8 heterocyclic, Optionally substituted C6-10 arylene or Optionally substituted 5-10 heteroarylene; wherein R6 and R6' are each independently H, Optionally substituted -C1-12 alkyl or Optionally substituted -C2-12 alkenyl; M is -(CH2)p-M1, wherein M1 is selected from NR7R8, optionally substituted saturated or partially unsaturated 3-8-membered heterocyclic groups containing at least one nitrogen atom, and optionally substituted 5-10-membered heteroaryl groups containing at least one nitrogen atom; R7 and R8 are each independently selected from H, optionally substituted -C1-6 alkyl, optionally substituted -C2-6 alkenyl, and optionally substituted -C2-6 ynyl; G1 is absent, or G2 is absent, or G3 is absent, or R11a and R11b are each independently H, -OH, or C1-6 alkyl; R12 is selected from -C3-10 alkyl, -C3-10 alkenyl, -C3-10 cycloalkyl, -C3-10 cycloalkenyl, -C6-10 aryl, and -unique groups containing 1, 2, or 3.The cycloalkyl group is a 3-8 membered heterocyclic group selected from N, O, S; a 5-10 membered heteroaryl group containing 1, 2, or 3 heteroatoms independently selected from N, O, S; a halogen; -OH; -OC3-10 alkyl; -NR13aR13b, wherein the cycloalkyl, aryl, heterocyclic, and heteroaryl groups are each optionally substituted with -C1-6 alkyl; R13a and R13b are each independently H or -C1-6 alkyl; p is an integer from 0 to 6; and q and r are each independently an integer from 1 to 3. 2. The ionizable sterol compound of claim 1, or its stereoisomers, pharmaceutically acceptable salts, or solvates, having the following formula, wherein: L1 and L2 are each independently devoid of, or are straight-chain or branched -C1-12 alkylene groups, wherein the alkylene groups are optionally substituted with OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), -OC1-6 alkyl, -C1-6 alkyl, -C2-6 alkenyl, -C3-8 cycloalkyl, and wherein the alkylene groups are optionally separated by one or more -O-, -S-, -NR6-, -CH=CH-, -C≡C-, -C(O)-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6--OC(O)NR6-, or -OC(O)O-; Claims 2 / 12 pages 3 CN 121378377 AX is selected from non-existent, ‑O‑, ‑S‑, ‑NR6‑, ‑NR6‑NR6'‑, ‑N=N‑, ‑CH=N‑, ‑N=CH‑, ‑CH=CH‑, ‑C≡ C‑,‑O‑NR6‑,‑S‑S‑,‑SO‑,‑SO2,‑C(O)‑,‑C(=S)‑,‑C(=NR6)‑,‑C(O)O‑,‑C(O)S‑,‑OC (O)‑,‑SC(O)‑,‑NR6C(O)‑,‑C(O)NR6‑,‑NR6SO2‑,‑SO2NR6‑,‑OC(O)O‑,‑NR6C(O)O‑,‑OC(O) NR6-, -SC(O)NR6-, -NR6C(O)NR6'-, -NR6C(O)S-, -P(O)(OR6)O-, -OP(O)(OR6)-, -OP(O)(OR6)O-, optionally substituted C3-8 cycloalkylene, optionally substituted 3-8 heteroalkylene, optionally substituted C6-10 arylene or optionally substituted 5-10 heteroalkylene, wherein the optional substituent is selected from -OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), -OC1-6 alkyl, -C1-6 alkyl, -C2-6 alkenyl, -C3-8 cycloalkyl;R6 and R6' are each independently H, -C1-12 alkyl, or -C2-12 alkenyl, each optionally substituted with -OH, -COC1-6 alkyl, -COOC1-6 alkyl, -NH2, -NHC1-6 alkyl, -N(C1-6 alkyl)2, oxo, halogen, cyano, nitro, -C(O)NH2, -C(O)NHC1-6 alkyl, -C(O)N(C1-6 alkyl)2, -OC1-6 alkyl, -C1-6 alkyl, -C2-6 alkenyl, or -C3-8 cycloalkyl; M is -(CH2)p-M1, wherein M1 is selected from NR7R8, a saturated or partially unsaturated 3-8 membered heterocyclic group containing at least one nitrogen atom, or a 5-10 membered heteroaryl group containing at least one nitrogen atom, wherein the heterocyclic group or heteroaryl group is optionally substituted with one or more OH, - COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), amidine, guanidinyl, -OC1-6 alkyl, and -C1-6 alkyl; R7 and R8 are each independently selected from H, -C1-6 alkyl, -C2-6 alkenyl, and -C2-6 ynyl, each optionally substituted by one or more groups selected from: OH, -COR6, -COOR6, -NR6R6', -C(O)N(R6R6'), amidine, guanidinyl, halogen, cyano, nitro, -OC1-6 alkyl, -(OC1-6 alkylene)n-OH, saturated or partially unsaturated 3-8 membered heterocyclic groups containing at least one nitrogen atom, and 5-10 membered heteroaryl groups containing at least one nitrogen atom, wherein the heterocyclic or heteroaryl group is optionally substituted by one or more OH, -COR6, - COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), amido, guanidino, -OC1-6 alkyl, and -C1-6 alkyl substituted; n is an integer from 1 to 4. 3. The ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt, or solvate according to claim 1 or 2, wherein R1a is selected from H, -C1-6 alkyl, and -C(O)C1-6 alkyl. Claims 3 / 12 Page 4 CN 121378377 A 5. The ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt, or solvate according to claim 1 to 2, wherein R1b is H. 6. The ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt, or solvate according to any one of claims 1 to 2, wherein R2 is H. 7. The ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt, or solvate according to any one of claims 1 to 6, wherein R3 is -CH3. 8. The ionizable sterol compound, its stereoisomer, or pharmaceutically acceptable salt according to any one of claims 1 to 7.Or a solvate, wherein W is a single bond with the carbon atom *, W is CH, and R4 is OH. 9. An ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt, or solvate according to any one of claims 1, 2, 4 to 8, wherein R5a and R5b are each independently H. 10. An ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt, or solvate according to any one of claims 1 to 9, wherein G1 is wherein one of R11a and R11b is H, and the other is a C1-3 alkyl, preferably methyl; G2 is wherein q is 2; G3 is absent; and R12 is selected from -C3-10 alkyl and -C3-10 alkenyl, preferably -C3-6 alkyl and -C3-6 alkenyl. 11. The ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt, or solvate according to claim 10, wherein R12 has the following formula: wherein R12a is selected from H, -CH3, -CH2CH3, =CHCH3. 12. The ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt, or solvate according to any one of claims 1 to 11, wherein Z is selected from the following fragments: Claims 4 / 12 pages 5 CN 121378377 A wherein R1a is H, -C1-6 alkyl, and -C(O)C1-6 alkyl, preferably H, -C1-3 alkyl, and -C(O)C1-3 alkyl. 13. An ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt or solvate according to any one of claims 2 to 12, wherein L1 is absent; and / or X is selected from -O-, -S-, -NR6-, -NR6-NR6'-, -O-NR6-, -C(O)-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6-, -OC(O)O-, -NR6C(O)O-, -OC(O)NR6-, -NR6C(O)NR6'-; preferably X is selected from -O-, -NR6-, -OC... (O)-, -NR6C(O)-, -OC(O)O-, -NR6C(O)O-, -OC(O)NR6-, -NR6C(O)NR6'-; and / or L2 is a straight-chain or branched -C1-12 alkylene group, optionally substituted with -OH, -NR6R6', halogen, -OC1-6 alkyl, and optionally separated by one or more -O-, -NR6-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6-, -NR6C(O)O-, -NR6C(O)NR6'-, -OC(O)O- or -OC(O)NR6-; wherein R6 and R6' are each independently H, -C1-6 alkyl or -C2-6 alkenyl; preferably each independently H or -C1-6 alkyl, optionallyThe sterol compound is optionally substituted with -OH, -NH2, -NHC1-6 alkyl, or -N(C1-6 alkyl)2, preferably optionally substituted with -OH. 14. The ionizable sterol compound according to claim 13, its stereoisomers, pharmaceutically acceptable salts, or solvated compounds, wherein: L2 comprises the repeating structural segment -[(CH2)m-O]t-, where m is an integer from 1 to 6 and t is an integer from 0 to 6; for example, m is an integer of 2 and t is an integer from 2 to 6; for example, m is an integer from 1 to 6 and t is 1; and / or L2 comprises the repeating structural segment -[(CH2)m-NR6]t-, where m is an integer from 1 to 6 and t is an integer from 0 to 6; for example, m is an integer of 2 Integers up to 4, t is an integer from 2 to 6; for example, m is an integer from 1 to 6, t is 1; and / or the alkylene group of L2 is separated by one or more -NR6C(O)O-, -NR6C(O)NR6'-, -OC(O)NR6- or -OC(O)O-; for example, -C1-6alkylene-O-CO-NR6-C1-6alkylene-, -C1-6alkylene-O-CO-O-C1-6alkylene-, -C1-6alkylene-NR6- CO-O-C1-6alkylene-, -C1-6alkylene-NR6-CO-NR6-C1-6alkylene-. 15. An ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt or solvate according to any one of claims 1 to 12, wherein the linker L or -L1-X-L2- has the following structure: Claims 6 / 12 page 7 CN 121378377 A Claims 7 / 12 page 8 CN 121378377 A Wherein, an asterisk * indicates a connection point with the steric ring, a single wavy line indicates a connection point with M, when there are multiple wavy lines, at least one indicates a connection point with M, and the rest indicate connection points with the alkyl branch of H or L2, m is an integer from 1 to 6, and t is an integer from 0 to 6. 16. An ionizable sterol compound, its stereoisomer, a pharmaceutically acceptable salt, or a solvate according to any one of claims 1 to 15, wherein: M is -(CH2)p-M1, wherein M1 is NR7R8, R7 and R8 are each independently selected from H and optionally substituted -C1-6 alkyl groups, wherein the alkyl group is optionally substituted by one or more -OH, -COOH, -NR6R6', oxo, halogen, cyano, nitro, or -OC1-6 alkyl groups, specifically optionally substituted by one or more -OH and / or -NR6R6'; for example, M is selected from: wherein the -C1-6 alkyl group is optionally substituted by -OH. 17. An ionizable sterol compound, its stereoisomer, a pharmaceutically acceptable salt, or a solvate according to any one of claims 1 to 15, wherein M is -(CH2)p-M1, wherein M1 is selected from the claims.Page 8 / 12, CN 121378377 A Each may be optionally substituted by one or more OH, -COOH, -NH2, oxo, halogen, cyano, nitro, -OC1-6 alkyl and C1-6 alkyl groups. 18. An ionizable sterol compound, its stereoisomer, pharmaceutically acceptable salt, or solvate according to any one of claims 1 to 17, excluding 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-propionate; 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-hexanoate; 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl-ethyl carbonate; 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl-butyl carbonate; 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl-1-H-imidazol-4-yl ethylcarbamate; 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl ethylcarbamate; L-histidine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl ester; L-leucine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl ester; L-isoleucine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl ester; L-Valine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-ester; L-Phenylalanine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-ester; L-Tryptophan 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-ester; L-Lysine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-ester; L-Tyrosine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl ester; and L-proline 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl ester. 19. A lipid carrier composition comprising an ionizable sterol compound of any one of claims 1 to 18, or a stereoisomer thereof, a pharmaceutically acceptable salt or solvate thereof, and phospholipids, structural lipids, and polymer-conjugated lipids, preferably in the form of lipid nanoparticles. 20. The lipid carrier composition of claim 19, wherein the ionizable sterol compound constitutes a molar percentage of the total lipids.The percentage is from about 15% to about 65%, preferably from about 30% to about 60%, more preferably from about 40% to about 60%, and most preferably about 50%. 21. The lipid carrier composition according to claim 19 or 20, wherein the phospholipid is selected from: dilauroyl lecithin (DLPC), dimyristoyl phosphatidylcholine (DMPC), dioleoyl lecithin (DOPC), dipalmitoyl phosphatidylcholine (DPPC), distearate phosphatidylcholine (DSPC), dioleoyl phosphatidylcholine (DUPC), palmitoyl oleoyl phosphatidylcholine (POPC), 1,2-di-O-octadecyl-sn-glycerol-3-phosphate choline (18:ODiether PC), 1-oleoyl-2-cholestyldimethylsuccinate-sn-glycerol-3-phosphate choline (OChemsPC), 1-hexadecyl-sn-glycerol-3-phosphate choline (C16 Lyso PC), 1,2-divinyl-sn-glycerol-3-phosphate choline, 1,2-Diarylacyl-sn-glycerol-3-phosphate choline, 1,2-Diarachidonicyl-sn-glycerol-3-phosphate choline, 1,2-bis(docosahexaenoyl)-sn-glycerol-3-phosphate choline, 1,2-dioleoyl-SN-glycerol-3-phosphate ethanolamine (DOPE), 1,2-diphydanyl-sn-glycerol-3-phosphate ethanolamine (ME 16.0PE), 1,2-distearatel-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-diarachidonicyl-sn-glycerol-3-phosphate ethanolamine, 1,2-divinyl-sn-glycerol-3-phosphate ethanolamine, 1,2-divinyl-sn-glycerol-3-phosphate ethanolamine, 1,2-Diaryl-sn-glycerol-3-phosphate ethanolamine, 1,2-dithiohexaenoic acid-sn-glycerol-3-phosphate ethanolamine, 1,2-bis(docosahexaenoic acid)-sn-glycerol-3-phosphate ethanolamine, 1,2-diol-sn-glycerol-3-phosphate-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), distearate-phosphatidyl-ethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE), 1-stearoyl-2-oleoylphosphatidylethanolamine (SOPE), 1-stearoyl-2-oleoylphosphatidylcholine (SOPC), or sphingomyelin, and mixtures thereof, preferably the phospholipids being DOPE or DSPC. 22. The lipid carrier composition according to any one of claims 19 to 21, wherein the phospholipid accounts for a molar percentage of the total lipids.The structural lipid is selected from one or more of cholesterol, coprosterol, sitosterol, ergosterol, and stigmasterol, preferably cholesterol. 23. The lipid carrier composition according to any one of claims 19 to 22, wherein the structural lipid accounts for about 20% to about 50% of the total lipids, preferably about 25% to about 50%, more preferably about 35% to about 50%. 25. The lipid carrier composition according to any one of claims 19 to 24, wherein the polymer-conjugated lipid is a PEG-modified lipid selected from one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, or PEG-modified dialkylglycerol, preferably selected from: 1,2-dimyristoyl-sn-glycerol methoxy polyethylene glycol (PEG-DMG), 1,2-distearate-sn-glycerol-3-phosphate ethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-distearate glycerol (PEG-DSG), PEG-dispalmitoyl, PEG-dioleoyl, PEG-distearate, PEG-diacylglycineamide (PEG-DAG), PEG-dispalmitoylphosphatidylethanolamine (PEG-DPPE), or PEG-1,2-dimyristyloxypropyl-3-amine (PEG-c-DMA), more preferably selected from 1 2,2-Dimyristoyl-sn-glycerol methoxy polyethylene glycol (PEG-DMG), 1,2-distearate-sn-glycerol-3-phosphate ethanolamine-N-[amino(polyethylene glycol)]] (PEG-DSPE). 26. The lipid carrier composition according to any one of claims 19 to 25, wherein the polymer-conjugated lipid accounts for about 1% to about 10% of the total lipids in molar percentage, preferably about 1% to about 5%, more preferably about 1% to about 2%. 27. The lipid carrier composition according to any one of claims 19 to 26, wherein the molar ratio of the ionizable sterol compound, phospholipid, structural lipid, and polymer-conjugated lipid is 30–60:5–20:25–50:1–5, preferably 40–60:5–15:30–50:1–2. 28. A lipid nanoparticle composition comprising the lipid carrier composition of any one of claims 19 to 27, and a therapeutic and / or preventive agent selected from nucleic acid molecules, peptides, proteins, and small molecule compounds, preferably nucleic acids. 29. The lipid nanoparticle composition of claim 28, wherein the nucleic acid is selected from spontaneous RNA (mRNA), short stem cells, etc.Interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecules, microRNA (miRNA), antisense RNA, ribozymes, Dicer-substrate RNA (dsRNA), hairpin RNA (shRNA), and mixtures thereof. 30. The lipid nanoparticle composition according to claim 28 or 29, wherein the mass ratio of the lipid carrier composition to the therapeutic or preventative agent is 10:1 to 30:1, preferably 12.5:1 to 25:1, more preferably 15:1, and / or the N / P (nitrogen-phosphorus ratio) of the lipid carrier composition to the nucleic acid is 3 to 12, preferably 6 to 10, more preferably 4 to 8. 31. The lipid nanoparticle composition according to any one of claims 28 to 30, wherein the encapsulation efficiency of the therapeutic agent is ≥50%; or ≥80%; or ≥90%; and / or the average particle size of the lipid nanoparticles is 100 nm to 200 nm; and / or the dispersibility index of the nanoparticle composition is 0.1 to 0.3. 32. A pharmaceutical composition comprising the lipid nanoparticle composition of any one of claims 28 to 31 and a pharmaceutically acceptable excipient. 33. An ionizable sterol compound of any one of claims 1 to 18, or a lipid carrier composition of any one of claims 19 to 27, for delivery to an individual as a therapeutic and / or preventative agent. 34. The lipid nanoparticle composition of any one of claims 28 to 31 or the pharmaceutical composition of claim 32, used as a medicament, preferably for treating an individual's disease or condition. 35. Use of the lipid nanoparticle composition of any one of claims 28 to 31 or the pharmaceutical composition of claim 32 in the preparation of a medicament for the treatment or prevention of a disease or condition in mammals, such as humans, characterized by a dysfunction or abnormality in the activity of a protein or peptide; for example, the disease or condition is selected from infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular diseases, renal vascular diseases, or metabolic diseases. Claims 11 / 12 pages 12 CN 121378377 A 36. A lipid nanoparticle composition of any one of claims 28 to 31 or a pharmaceutical composition of claim 32, for the treatment or prevention of a disease or condition in mammals, such as humans, characterized by a dysfunction or abnormality in the activity of a protein or polypeptide; for example, the disease or condition is selected from infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular diseases, renal vascular diseases, or metabolic diseases. 37. A method of delivering a therapeutic or preventive agent to mammalian cells or organs, comprising administering to a subject the lipid nanoparticle composition of any one of claims 28 to 31 or the pharmaceutical composition of claim 32, causing the cells or organs to be exposed to...The lipid nanoparticles or pharmaceutical compositions comprising them are contacted; preferably, the mammal is a human; preferably, the lipid nanoparticles or pharmaceutical compositions comprising them are administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation. 38. A method of treating or preventing a disease or condition in a mammal, such as a human, the method comprising administering to the mammal a therapeutically or preventively effective amount of any one of claims 28 to 31 of the lipid nanoparticle composition or the pharmaceutical composition of claim 32; for example, the disease or condition is characterized by a dysfunction or abnormality in the activity of a protein or polypeptide; for example, the disease or condition is selected from infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular diseases, renal vascular diseases, or metabolic diseases; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation. Claims 12 / 12 pages 13 CN 121378377 A Ionizable sterol derivatives for delivery of therapeutic agents and their uses therein

[0001] Cross-reference

[0002] This application claims priority to Chinese Invention Patent Application 2024113028634, filed on September 18, 2024. Technical Field

[0003] This disclosure relates to ionizable sterol derivatives, lipid nanoparticles comprising the same, compositions thereof, and their pharmaceutical uses. Background Art

[0004] The efficient targeted delivery of bioactive substances such as small molecule drugs, proteins, and nucleic acids is an ongoing medical challenge. Furthermore, gene therapy uses genetic material to alter the expression of target genes or change the biological characteristics of living cells to meet therapeutic needs, and its success hinges on whether therapeutic drugs can be safely and effectively delivered into target cells via a carrier in vivo. Due to the achievements researchers have made in recent years in the interpretation of the human genome, gene therapy has become a hot topic in the industry, with nucleic acids attracting considerable attention. Several gene products have been approved by regulatory agencies for various applications, such as the use of mRNA vaccines to combat COVID-19.

[0005] Due to their negative charge, high molecular weight, and hydrophilicity, nucleic acids are relatively unstable and have low cell permeability, making the delivery of nucleic acids to their active sites within cells the most challenging aspect of gene therapy. RNA delivery, in particular, requires frequent administration due to its short duration of activity and low intracellular retention, creating a trade-off between payload and carrier toxicity. Therefore, further methods are needed to facilitate the delivery of therapeutic and / or preventative drugs, such as nucleic acids, to cells.

[0006] Commonly used nucleic acid delivery vectors include viral vectors and non-viral vectors. Although viral vectors are highly efficient delivery systems for transfection and treatment, they contain immunogenic viral proteins and target gene loading.Limited quantity and high price have led to widespread attention being paid to lipid nanoparticles (LNPs) as non-viral carriers due to their advantages such as good in vitro stability, in vivo degradation, and safety.

[0007] However, endosome escape remains a major obstacle in LNP drug delivery, and the development of ionizable lipids with high transfection efficiency is the cornerstone of this field. Ionizable cationic lipids are an important component of the current mainstream non-viral lipid carriers LNPs, and are usually composed of a head group, a linker unit, and a tail chain with at least one ionizable site. They are neutral under physiological conditions, but positively charged in the acidic environment of the endosome, and electrostatically bind to negatively charged hydrophilic nucleic acid molecules. Although various types of ionizable lipids have been developed or reported for the delivery of active agents such as nucleic acids, the field still needs ionizable lipids and LNP delivery systems with improvements in safety, delivery efficiency, or specificity.

[0008] To this end, this disclosure constructs a class of chemical derivatives based on sterols, wherein sterol structures and their derivatives are used as tail chains, and at specific sites are connected to ionizable head groups containing amines, guanidines, heterocyclic groups, etc., through biodegradable linking units to construct amphiphilic lipid compounds, thereby providing a new class of cationic lipid compounds and enriching the current types of cationic lipids. The preparation of the ionizable lipid compounds uses readily available raw materials, mild reaction conditions, high product yield, low equipment requirements, and simple operation. Moreover, the LNPs prepared based on them can deliver and transfect nucleic acids with satisfactory efficacy and show excellent stability, thereby meeting the above requirements.

[0009] Brief Description of this Disclosure

[0010] This disclosure provides ionizable lipid compounds based on sterols, and lipid nanoparticle compositions containing the compounds. The lipid nanoparticle compositions are suitable for delivering bioactive molecules, especially for delivering negatively charged nucleic acid molecules, and have the advantages of high encapsulation efficiency, low toxicity, high expression, and good stability. This disclosure also provides methods and uses for delivering active agents to subjects using such compositions.

[0011] Specifically, a first aspect of the invention provides an ionizable sterol compound of formula A, or a stereoisomer thereof, a pharmaceutically acceptable salt or solvate thereof,

[0012] Z-L-(M)r A

[0013] wherein each variable is as defined herein.

[0014] The compounds described above and the general formulas and specific compounds disclosed in the context of this disclosure, as well as their stereoisomers, pharmaceutically acceptable salts or solvates, are referred to herein as “compounds of this disclosure”.

[0015] In a second aspect, this disclosure provides lipid carrier compositions, specifically lipid particles, and more specifically lipid nanoparticles.

[0016] In a third aspect, this disclosure provides lipid nanoparticle compositions comprising compounds of this disclosure or lipid carrier compositions of this disclosure, and one or more therapeutic / preventive agents.

[0017] In a fourth aspect, this disclosure provides pharmaceutical compositions comprising lipid nanoparticle compositions of this disclosure and pharmaceutically acceptable excipients.

[0018] In a fifth aspect, this disclosure provides uses of the compounds of this disclosure, lipid carrier compositions, lipid nanoparticle compositions, or pharmaceutical compositions for the delivery of therapeutic and / or preventive agents to an individual, for the treatment or prevention of a disease or condition, and for the preparation of pharmaceuticals, specifically in the preparation of pharmaceuticals for the delivery of therapeutic and / or preventive agents to an individual, for the treatment of a disease or condition in an individual, or for the introduction of nucleic acids into cells.

[0019] In a sixth aspect, this disclosure provides a method of delivering therapeutic and / or preventive agents to an individual, the method comprising administering the lipid nanoparticle composition or pharmaceutical composition to an individual in need.

[0020] In a seventh aspect, this disclosure provides a method for treating or preventing a disease or ailment, the method comprising administering an effective amount of the lipid nanoparticle composition or pharmaceutical composition to an individual in need.

[0021] In an eighth aspect, this disclosure provides a method for introducing nucleic acids into cells, the method comprising contacting the cells with the lipid carrier composition; and the use of the lipid carrier composition to introduce nucleic acids into cells. Brief Description of the Drawings

[0022] Figure 1A shows the mass spectrometry spectrum of ST-001 ([M+1]+=514.6).

[0023] Figure 1B shows the nuclear magnetic resonance spectrum of ST-001.

[0024] Figure 2A shows the particle size and morphology detection results (0 days) of the LNP of Example.

[0025] Figure 2B shows the morphology detection results (0 days) of the LNP of Example.

[0026] Figure 3 shows the change in hydrated particle size of the LNP of Example after storage at 100mM Tris-HCl / 4°C for different times.

[0027] Figure 4 shows the morphological changes of the Example LNP after storage at 100 mM Tris-HCl / 4℃ for 30 days, observed by transmission electron microscopy (TEM).

[0028] Figure 5 shows the changes in encapsulation efficiency of the Example LNP after storage at 100 mM Tris-HCl / 4℃ for different times.

[0029] Figure 6 shows an image of the Example LNP transfected with green fluorescent protein (GFP) in cells. Specification 2 / 41 pages 15 CN 121378377 A

[0030] Detailed Description of the Present Disclosure

[0031] Definitions

[0032] The following words, phrases and symbols used in this disclosure have the meanings described below, unless the context otherwise requires. Technical and scientific terms not specifically defined herein are generally understood by one of ordinary skill in the art to which this disclosure pertains.The meaning of "comprising" or "including" as used herein is intended to indicate the presence of the mentioned features, ingredients, or steps, but they do not exclude the presence or addition of one or more other features, ingredients, or steps. Unless otherwise specified, "comprising" or "including" as used herein covers the situation consisting of the mentioned features, ingredients, or steps.

[0034] The term "about" as used herein means within ±20%, for example, within ±10%, within ±5%, of a given value or range.

[0035] All numerical ranges herein should be understood as disclosing every value and subset of values ​​within that range, regardless of whether they are specifically disclosed separately. For example, when referring to any numerical range, it should be considered as referring to every value within that range, such as every integer within that range, for example, C1-6 in this document means including 1, 2, 3, 4, 5, or 6 Cs, and different ranges consisting of different values ​​within that range. This disclosure relates to all values ​​falling into these ranges, all smaller ranges, and upper or lower limits of numerical ranges.

[0036] When used to connect two or more options, “and / or” as used herein should be understood as any one of the options or any combination of two or more of the options.

[0037] As used herein, “alkyl” refers to a straight-chain or branched saturated hydrocarbon having one or more carbon atoms, such as a straight-chain or branched saturated hydrocarbon group having 1-22 carbon atoms (C1-12), 6-22 carbon atoms (C6-22), 6-20 carbon atoms (C6-20), 6-18 carbon atoms (C6-18), 6-16 carbon atoms (C6-16), 6-12 carbon atoms (C6-12), 8-12 carbon atoms (C8-12), 5-9 carbon atoms (C5-9), 6-8 carbon atoms (C6-8), 2-10 carbon atoms (C2-10), 2-8 carbon atoms (C2-8), 1-12 carbon atoms (C1-12), 1-6 carbon atoms (C1-6), 1-4 carbon atoms (C1-4), or 1-3 carbon atoms (C1-3), for example, a straight-chain hydrocarbon group. Wherein, the expression Cm-n alkyl refers to an alkyl group having m-n carbon atoms, including alkyl groups having any number of carbon atoms between m and n, and alkyl groups having any number of carbon atoms between m and n. For example, "C1-6 alkyl" refers to a straight-chain or branched alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms; examples of C6-22 alkyl include, but are not limited to, C6-18 straight-chain or branched alkyl, C8-12 straight-chain or branched alkyl, or C6-12 straight-chain or branched alkyl; examples of C1-6 alkyl include, but are not limited to, methyl, ethyl, propyl (e.g., n-propyl, isopropyl), butyl (e.g., n-butyl, isobutyl, sec-butyl, and tert-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), hexyl, etc.

[0038] As used herein, the term "alkenyl" refers to a straight-chain or branched unsaturated hydrocarbon group containing one or more, for example, 1, 2 or 3 carbon-carbon double bonds (C=C), such as a straight-chain or branched unsaturated hydrocarbon group with 2–22 carbon atoms (C2–22), 6–22 carbon atoms (C6–22), 6–20 carbon atoms (C6–20), 6–18 carbon atoms (C6–18), 6–16 carbon atoms (C6–16), 6–12 carbon atoms (C6–12), 8–12 carbon atoms (C8–12), 5–9 carbon atoms (C5–9), 6–8 carbon atoms (C6–8), 2–12 carbon atoms (C2–12), 2–6 carbon atoms (C2–6), 2–4 carbon atoms (C2–4) or 2–3 carbon atoms (C2–3). Examples of C6-22 alkenyl groups include, but are not limited to, C6-18 straight-chain or branched alkenyl groups, C8-12 straight-chain or branched alkenyl groups, or C6-12 straight-chain or branched alkenyl groups. Examples of C2-6 alkenyl groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 2-butenyl, etc.

[0039] As used herein, the term "alkynyl" refers to a straight-chain or branched unsaturated hydrocarbon group having two or more carbon atoms, containing one or more, for example, 1, 2 or 3 carbon-carbon triple bonds (C≡C), such as 2-22 carbon atoms (C2-22), 6-22 carbon atoms (C6-22), 6-20 carbon atoms (C6-20), 6-18 carbon atoms (C6-18), 6-16 carbon atoms (C6-16), 6-12 carbon atoms (C6-12), 8-12 carbon atoms (C8-12), 5-9 carbon atoms (C5-9), 6-8 carbon atoms (C6-8), and 2-12 carbon atoms. (Specification 3 / 41 page 16 CN 121378377 A) (C2-12), 2-6 carbon atoms (C2-6), 2-4 carbon atoms (C2-4), or 2-3 carbon atoms (C2-3) straight-chain or branched unsaturated hydrocarbon groups. Examples of C6-22 ynyl groups include, but are not limited to, C6-18 straight-chain or branched ynyl groups, C8-12 straight-chain or branched ynyl groups, or C6-12 straight-chain or branched ynyl groups. Examples of C2-6 ynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 2-butynyl, etc.

[0040] As used herein, the terms “alkylene” and “alkenyl” refer to divalent groups of alkyl or alkenyl groups as defined herein. Examples of alkylene groups include, but are not limited to, straight-chain or branched C1-12 alkylene groups, C2-10 alkylene groups, and C1-6 alkylene groups. Examples of alkenyl groups include, but are not limited to, straight-chain or branched C2-12 alkenyl groups, C2-10 alkenyl groups, and C2-6 alkenyl groups.

[0041] As used herein, the term "cycloalkyl" refers to a non-aromatic carbon ring and optionally contains one or more double or triple bonds.Bonds, such as C3-14 cycloalkyl, C3-8 cycloalkyl, C3-6 cycloalkyl. Unless otherwise stated, the cycloalkyl described herein refers to optionally substituted cycloalkyl.

[0042] As used herein, the term "heterocyclic" or "heterocyclic group" refers to a monocyclic or polycyclic non-aromatic system wherein at least one ring comprises at least one heteroatom, such as 1, 2, 3, 4, or 5 heteroatoms, which may be, for example, N, O, or S atoms, preferably N atoms. The heterocycle may have 3, 4, 5, 6, 7, 8, 9, 19, 11, 12, 13, 14, or 15 member rings, such as 3-14-membered heterocycles, 3-12-membered heterocycles, 3-8-membered heterocycles, 3-6-membered heterocycles, and 4-7-membered heterocycles. The heterocycle may also optionally comprise one or more double or triple bonds, i.e., it may be saturated (i.e., heterocyclic alkyl) or unsaturated. In some embodiments of this disclosure, the heterocyclic group may be a 3-8 membered heterocyclic group containing at least one nitrogen atom, and optionally also contains 1 to 3, for example 1 to 2, heteroatoms selected from N, O, and S. Examples of heterocycles include, but are not limited to: nitrogen-containing heterocyclic butyl groups, oxocyclic butyl groups, thiocyclic butyl groups, pyrrolidinyl groups (e.g., 1-pyrrolidinyl, ...), and others. 2-pyrrolidinyl and 3-pyrrolidinyl), tetrahydrofuranyl (e.g., 1-tetrahydrofuranyl, 2-tetrahydrofuranyl and 3-tetrahydrofuranyl), tetrahydrothiophenyl (e.g., 1-tetrahydrothiophenyl, 2-tetrahydrothiophenyl and 3-tetrahydrothiophenyl), piperidinyl (e.g., 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), tetrahydropyranyl (e.g., 4-tetrahydropyranyl), tetrahydrothiophenyl (e.g., 4-tetrahydrothiophenyl), morpholinyl (e.g., morpholino), thiomorpholinyl, dioxane, piperazine or azacycloheptyl, diazacycloheptyl, e.g., 1,4-diazacycloheptyl, 2-aza-bicyclo[2.2.1]heptyl, 2-aza-bicyclo[2.2.2]octyl, 3,6-diaza-bicyclo[3.1.1]heptyl, 3-diaza-bicyclo[3.2.1]octyl, 1,7-dioxa[4.5]decyl, 2-oxa-7-azaspiro[4.4]nonyl, 7-oxaspiro[3.5]nonyl, 5-oxaspiro[2.4]heptyl, octahydropyrrolo[3.4-c]pyrrole, octahydro-1H-isoindolyl, octahydrobenzo[b][1.4]dioxin. The atoms in the heterocyclic group attached to the remainder of the compound can be carbon atoms or heteroatoms, as long as chemically feasible. The heterocyclic group in the compounds disclosed herein can be unsubstituted or substituted with one or more substituents as defined.

[0043] As used herein, the term "aryl" refers to a monocyclic or fused polycyclic aromatic ring structure having a specified number of ring atoms. Specifically, the term includes groups comprising, for example, 6 to 10, preferably 6, ring members. Specific aryl groups include phenyl and naphthyl. The aryl groups in the compounds disclosed herein may be unsubstituted or substituted with one or more of the defined substituents.

[0044] As used herein, the term "heteroaryl" refers to a mono- or bicyclic ring system having 5-10 (5-10-membered), for example 5-9 (5-9-membered), for example 5-6 (5-6-membered), or 8-9 (8-9-membered) ring atoms, wherein at least one ring is an aromatic ring containing a heteroatom selected from N, O, and S. In embodiments of this disclosure, the heteroaryl is a 5-10-membered heteroaryl containing at least one nitrogen atom. For example, the heteroaryl comprises one or more, for example 1, 2, 3, or 4, preferably 1, 2, or 3, heteroatoms independently selected from N, O, and S (preferably N), and at least one heteroatom is N, with the remaining ring atoms being carbon atoms. The heteroaryl groups include, but are not limited to:

[0045] 5-6 member monocyclic heteroaryl groups, comprising one or more, for example, 1, 2 or 3 heteroatoms independently selected from N, O and S (preferably N), and at least one heteroatom is N, for example, comprising 1, 2 or 3 N heteroatoms, and the remaining ring atoms are carbon atoms, for example, but not limited to imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, isoxazolyl, triazinyl, oxazolyl, thiadiazolyl, pyridazinyl; and

[0046] 8-10 member bicyclic heteroaryl groups, comprising one or more, for example, 1, 2, 3 or 4, preferably 1, 2 or 3 heteroatoms independently selected from A, O and S (preferably N), and at least one heteroatom is N, and the remaining ring atoms are carbon atoms, wherein at least one ring is an aromatic ring; for example, 8-9 member bicyclic heteroaryl groups, for example, indole, indole-3-yl.

[0047] As used herein, the terms “cycloalkylene,” “heterocyclicene,” “arylene,” and “heteroarylene” refer to the divalent groups of “cycloalkyl,” “heterocyclic,” “aryl,” and “heteroaryl,” respectively, as defined herein.

[0048] As used herein, the term “optional” means that the event or situation described below may or may not occur, including both the occurrence and non-occurrence of the event or situation. For example, “optionally substituted with…” includes both unsubstituted and chemically feasible substitution with one or more of the described substituents. “Optionally containing” includes both inclusion and non-inclusion.

[0049] Unless otherwise stated, the optional substituents referred to in the group definitions herein are selected from, but not limited to, halogen atoms (e.g., chlorine, bromine, fluorine, or iodide), carboxylic acids (e.g., -C(O)OH), alcohols (e.g., -OH), esters (e.g., -C(O)OR or -OC(O)R), aldehydes (e.g., -C(O)H), carbonyl groups (e.g., -C(O)R, or represented by C=O), acyl halides (e.g., -C(O)X, where X is selected from bromides, fluorides, chlorides, and iodides), carbonates (e.g., -OC(O)OR), and alkoxy groups.(e.g., -OR), acetal, phosphate, thiol (e.g., -SH), sulfoxide (e.g., -S(O)R), sulfurous acid (e.g., -S(O)OH), sulfonic acid (e.g., -S(O)2OH), thioaldehyde (e.g., -C(S)H), sulfate, sulfonyl (e.g., -S(O)2-), amide (e.g., -C(O)NR2 or -N(R)C(O)R), azide (e.g., -N3), nitro (e.g., -NO2), cyano (e.g., -CN), isocyano (e.g., -NC), acyloxy (e.g., -OC(O)R), amino (e.g., -NR2, -NRH or -NH2), carbamoyl (e.g., -OC(O)NR2, -OC(O)NRH or -OC(O)NH2), sulfonamide, alkyl, alkenyl and cycloyl (e.g., cycloalkyl or heterocyclic). In any of the foregoing, R is an alkyl or alkenyl group as defined herein. In some embodiments, the substituent itself may be further substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents as defined herein. For example, a C1-6 alkyl group may be further substituted with 1, 2, 3, 4, 5, or 6 substituents as described herein.

[0050] The representations appearing in the compound structures herein may be single or double bonds as appropriate, and the ---- indicates the presence or absence of the bond as appropriate.

[0051] The expression “spaced by” as used herein in describing compound groups includes the case where the spacer group is in the middle of the group, and also the case where the spacer group is at any end of the group.

[0052] The terms “compound” or “compound of this disclosure” as used herein refer to all isomers and isotopic variants (e.g., one or more deuterated variants) including the described structure. Furthermore, pharmaceutically acceptable salts, solvates, and hydrates of the described structure are also included.

[0053] As used herein, the term “isomer” means any geometric isomer, tautomer, zwitterion, stereoisomer, enantiomer, or diastereomer of a compound. A compound may contain one or more chiral centers and / or double bonds, and thus may exist in stereoisomeric form, such as double-bonded isomers (i.e., geometric E / Z isomers) or diastereomers. Those skilled in the art will also understand that this disclosure includes all individual stereoisomers (e.g., enantiomers), racemic mixtures, or mixtures of partially separated or partially enriched isomers of the defined compound, and, where appropriate, individual tautomers thereof.

[0054] As used herein, the term “pharmaceuticalally acceptable salt” refers to a salt of a free acid or base of a compound that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to a therapeutic or prophylactic individual. For example, acid addition salts include, for instance, addition salts derived from inorganic and organic acids, wherein the inorganic acids include, for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and nitric acid, and the organic acids include, for example, p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, and lactic acid.Fumaric acid, etc. For a general description of pharmaceutically acceptable salts, see, for example: SMBerge et al., “Pharmaceutical Salts”, J. Pharm. Sci., 1977, 66: 1-19, and Handbook of Pharmaceutical Salts, 5 / 41 pages, CN 121378377 A Properties, Selection, and Use, edited by Stahl and Wermuth, Wiley-VCH and VHCA, Zurich, 2002.

[0055] As used herein, the terms “pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” refer to an excipient or carrier that is compatible with (in some embodiments, stabilizes) the active ingredient or lipid particles in the composition and is harmless to the individual being treated. Suitable pharmaceutically acceptable excipients or carriers are disclosed in the standard reference in the art (Remington's Pharmaceutical Sciences).

[0056] As used herein, the term "linking unit" refers to a linker group that covalently connects two parts but breaks down under physiologically relevant conditions to sever the covalent connection between the two parts, i.e., a cleavable group. Linking units may include one or more groups, including but not limited to phosphate groups (e.g., phosphates, borosiphosphates, thiophosphates, selenium phosphates, and phosphates), alkyl groups, esters, amides, carbonates, sulfonamides, or glycerols. Typically, the cleavable group is cleaved more rapidly in the intracellular environment than outside the cell, resulting in the preferred release of the loaded drug within the target cell. Cleavage may be enzymatic or non-enzymatic and may leave a portion of the linker group attached to the loaded drug, or may release the loaded drug without any linker residues.

[0057] As used herein, the term "lipid component" is a component of a nanoparticle composition comprising one or more lipids. For example, a lipid component may include one or more cationic / ionizable lipids, polymer-conjugated lipids such as PEGylated lipids, structural lipids, or other lipids such as phospholipids.

[0058] As used herein, the term "ionizable lipid" refers to lipids having groups or atoms capable of becoming charged (ionized) with respect to ambient pH, such that they exist in a positively charged (e.g., low pH) or neutral (e.g., higher pH) form depending on pH. The compounds disclosed herein are ionizable lipids. Under different pH conditions, the ionization of ionizable lipids affects the surface charge of lipid nanoparticles.

[0059] As used herein, the term "polymer-conjugated lipid" refers to lipids conjugated with a hydrophilic polymer, including but not limited to polyethylene glycol (PEG), polyvinylpyrrolidone, polyethylene methyl ether, and polyhydroxypropyl methylpropene.Esters, polyhydroxypropyl methacrylamide, polyhydroxyethyl acrylate, polymethacrylamide, polydimethacrylamide, polymethyloxazoline, polyethyloxazoline, etc. In specific embodiments, the hydrophilic polymer-conjugated lipid is a PEG lipid.

[0060] The term "PEG lipid" as used herein includes, but is not limited to: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol and PEG-modified dialkylglycerol and mixtures thereof. For example, the PEG lipid is selected from 1,2-dimyristoyl-sn-glycerol methoxy polyethylene glycol (PEG-DMG), 1,2-distearate-sn-glycerol-3-phosphate ethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-distearate-glycerol (PEG-DSG), PEG-dipalmitoyl, PEG-dioleyl, PEG-distearate, PEG-diacylglycamide (PEG-DAG), PEG-dispalmitoylphosphatidylethanolamine (PEG-DPPE), or PEG-1,2-dimyristoyloxypropyl-3-amine (PEG-c-DMA). The PEG lipid is preferably 1,2-dimyristoyl-sn-glycerol methoxy polyethylene glycol (PEG-DMG) or 1,2-distearate-sn-glycerol-3-phosphate ethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), such as 1,2-dimyristoyl-sn-glycerol methoxy polyethylene glycol 2000 (PEG2k-DMG) or 1,2-distearate-sn-glycerol-3-phosphate ethanolamine-N-[amino(polyethylene glycol 2000)] (PEG2k-DSPE).

[0061] As used herein, the term "phospholipid" includes a phosphate ester moiety and one or more carbon chains, such as saturated or unsaturated fatty acid chains (e.g., having 1 to 20 carbon atoms). Phospholipids may contain one or more unsaturated bonds (e.g., double or triple bonds). Certain phospholipids can promote fusion with membranes. For example, cationic phospholipids can interact with one or more negatively charged phospholipids in a membrane (e.g., a cell membrane or intracellular membrane). The fusion of phospholipids with the membrane allows one or more elements of a lipid-containing composition (see page 6 / 41, 19 CN 121378377 A) to cross the membrane, thereby allowing, for example, the delivery of one or more elements to the cell.

[0062] As used herein, the term "structural lipid" refers to a steroid or a lipid containing a steroid moiety, such as a sterol and / or a lipid containing a sterol moiety. In a specific embodiment, the structural lipid is cholesterol, which may be a naturally occurring or synthetic compound having a cyclopentanoperhydrophenanthrene backbone. The structural lipids disclosed herein may also be cholesterol derivatives, i.e., cholesterol molecules having cyclopentanoperhydrophenanthrene and one or more additional functional groups.

[0063] As used herein, the term "sterol" refers to a group of naturally occurring or synthetic steroidal compounds or their salts or esters having a cyclopentane-polyhydrophenanthrene skeleton and one or more OH groups. Sterols are generally classified into two classes, phytosterols or animal sterols, including but not limited to cholesterol, β-sitosterol, codostrol, ergosterol, campesterol, stigmasterol, brassicosterol, tomatine, hydrolyzed tomatine, ursolic acid, α-tocopherol, etc.

[0064] As used herein, the term "delivery" refers to the delivery of an entity to a target. For example, delivery of a therapeutic and / or preventative agent to an individual may involve administering lipid nanoparticles comprising the therapeutic and / or preventative agent to the individual (e.g., via intravenous, intramuscular, intradermal, or subcutaneous routes). Administering lipid nanoparticles to mammals or mammalian cells may involve contacting one or more cells with a nanoparticle composition.

[0065] As used herein, the terms “specific delivery” or “specific delivery” or “enhanced delivery” mean that, compared to non-target tissues, a greater (e.g., at least 1.5 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times) amount of therapeutic and / or preventative medicine is delivered via nanoparticles to the target tissue (e.g., mammalian liver, spleen, stomach, intestine). It should be understood that “specific delivery” or “specific delivery” or “enhanced delivery” of nanoparticles to the target tissue can be determined in treated subjects or in animal models (e.g., rat models).

[0066] As used herein, the terms “therapeutic and / or preventative agent,” “therapeutic agent,” “preventative agent,” “active substance,” or “active agent” mean any agent that, when administered to a subject, has a therapeutic, diagnostic, and / or preventative effect and / or causes the desired biological and / or pharmacological effect, including but not limited to cytotoxins, radioactive ions, chemotherapeutic agents, small molecule drugs, proteins, and nucleic acids.

[0067] In a specific embodiment, the therapeutic and / or preventive agent may be selected from ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), such as natural or modified RNA or DNA. For example, the RNA is selected from single-stranded RNA, double-stranded RNA (dsRNA), partially double-stranded RNA and mixtures thereof, and / or the RNA is selected from circular RNA, linear RNA and mixtures thereof. In this regard, the therapeutic and / or preventive agent includes, but is not limited to: messenger RNA (mRNA), short interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecules, microRNA (miRNA), antisense RNA, ribozymes, Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA) and mixtures thereof. mRNA includes, for example, one or more of stem-loop, chain-terminating nucleoside, polyA sequence, polyadenylation signal and / or 5' cap structure. mRNA may include one or more modified nucleosides, nucleosides or nucleotides, inIn this case, it can be referred to as "modified mRNA" or "mmRNA".

[0068] The DNA molecule can be double-stranded DNA, single-stranded DNA (ssDNA), or a molecule that is partially double-stranded DNA, i.e., having a double-stranded portion and a single-stranded portion. The DNA molecule can be triple-stranded or partially triple-stranded, i.e., having a triple-stranded portion and a double-stranded portion. The DNA molecule can be a circular DNA molecule or a linear DNA molecule. DNA therapeutics and / or preventative agents can be DNA molecules capable of transferring genes into cells, for example, encoding and expressing transcripts. In other embodiments, the DNA molecule is a synthetic molecule, such as a synthetic DNA molecule produced in vitro. For example, the DNA molecule is a recombinant molecule. Non-limiting examples of DNA therapeutics and / or preventative agents include plasmid expression vectors and viral expression vectors.

[0069] As used herein, the term "lipid carrier composition" refers to a composition comprising one or more lipids, including lipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), and lipid complexes. Specifically, it refers to lipid nanoparticles, typically with a particle size on the order of micrometers or smaller, and may comprise a lipid bilayer. The lipid carrier composition serves as a carrier for therapeutic and / or preventative agents, delivering the latter into the cell.

[0070] As used herein, the term "lipid nanoparticle composition" refers to a composition comprising one or more lipids or the lipid carrier composition disclosed herein, and one or more therapeutic and / or preventative agents, preferably lipid nanoparticles (LNPs), having a nanoscale (1-1000 nm) size, and being spherical or polyhedral particles with an electron-dense core. Due to the presence of ionizable lipids, LNPs can encapsulate negatively charged nucleic acids at the core of the particle through mutual adsorption of positive and negative charges. For example, the diameter of the lipid nanoparticle composition is about 50-500 nm, for example, about 50-350 nm. Therapeutic or prophylactic agents such as nucleic acids may be encapsulated in the lipid portion of lipid nanoparticles or in an aqueous space encapsulated by some or all of the lipid portions of lipid nanoparticles, thereby protecting them from enzymatic degradation or other undesirable effects induced by host organism or cellular mechanisms, such as adverse immune responses.

[0071] The term “encapsulation ratio” as used herein refers to the amount of therapeutic and / or prophylactic agent that becomes part of the lipid particle composition relative to the initial total amount of therapeutic and / or prophylactic agent used in the preparation of lipid particles. For example, if 97 mg of the therapeutic and / or prophylactic agent out of 100 mg initially provided to the composition is encapsulated in lipid particles, an encapsulation ratio of 97% may be given. As used herein, “encapsulation” may mean complete, substantial, or partial encapsulation, closure, enclosure, or sealing.

[0072] The term “polydispersity index” or “PDI” as used herein is a ratio describing the uniformity of the particle size distribution of a system.A smaller value (e.g., less than 0.3) indicates a narrower particle size distribution.

[0073] The term “particle size” or “average particle size” as used herein describes the average diameter of lipid particles.

[0074] The term “zeta potential” as used herein describes the electrokinetic potential of lipids in a particle composition.

[0075] The term “N / P ratio” or “nitrogen / phosphorus ratio” as used herein refers, for example, in a composition comprising lipid particles and RNA such as mRNA, the molar ratio of ionizable nitrogen atoms in the lipids (within a physiological pH range) to phosphate groups in the RNA.

[0076] The term “expression” of a nucleic acid sequence as used herein refers to the translation of mRNA into a polypeptide or protein and / or post-translational modifications of a polypeptide or protein. The term “transfection” as used herein refers to the introduction of a species (e.g., RNA) into cells, and transfection can be performed, for example, in vitro, ex vivo, or in vivo.

[0077] The term “treatment” as used herein refers to the administration of the composition described herein to a subject, such as a mammal or human, suffering from or exhibiting symptoms of a disease, to cure, alleviate, or reduce said disease or its symptoms. Preferably, the treatment is curative or ameliorative.

[0078] As used herein, the term “prevention” means administering the composition described herein to a subject, such as a mammal, such as a human, suspected of having or susceptible to a disease, such as reducing the risk of contracting the defined disease or preventing the onset of the disease. The term “prevention” includes the use of the composition of this disclosure prior to the diagnosis or determination of any clinical and / or pathological symptoms.

[0079] As used herein, the term “effective amount” means an amount of therapeutic and / or preventive agent (e.g., nucleic acid, drug, composition, therapeutic agent, diagnostic agent, preventive agent, etc.) to be delivered sufficient to produce a beneficial effect, which, when administered to an individual suffering from or susceptible to an infection, disease, and / or condition, is sufficient to treat said infection, disease, and / or condition, alleviate, reduce, improve its symptoms, inhibit its progression, reduce its severity, diagnose, prevent, and / or delay its onset.

[0080] As used herein, the term “application” means the physical delivery of one or more therapeutic and / or preventative agents to an individual using a variety of methods known to those skilled in the art and delivery systems of this disclosure, such as LNP, including, for example, oral, intravenous (e.g., infusion, drip, or injection), intramuscular, subcutaneous, intradermal, intraperitoneal, spinal, local, or other parenteral administration routes. As used herein, the term “parenteral administration” refers to administration methods other than gastrointestinal and local administration, typically via intravenous, and non-limitingly includes intramuscular, intra-articular, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, tracheal, subcutaneous, subarticular, intra-articular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injections and infusions, as well as in vivo electroporation. Accordingly, the active agents in the combinations of this disclosure can be formulated into capsules, tablets, injections (including infusions or injection solutions).Syrups, sprays, lozenges, liposomes, or suppositories, etc.

[0081] The terms “individual,” “subject,” or “patient” as used herein refer to mammals and non-mammals who may seek or need treatment, need treatment, are receiving treatment, will receive treatment, or are receiving care for a specific disease. Mammals include, but are not limited to, humans; non-human primates, such as cattle, horses, sheep, pigs, rabbits, dogs, and cats. “Individual” is not limited to a specific age or sex. Preferably, the individual, subject, or patient is a human. Detailed Description

[0082] I. Ionizable Sterol Compounds of the Present Disclosure

[0083] The compounds of the present disclosure use a sterol structure linked at a specific site as a hydrophobic tail chain and a tertiary amine structure or a nitrogen-containing heterocycle or heteroaryl group as an ionizable head group. The two are linked by a linking unit containing a biodegradable chemical bond. The constructed amphiphilic compounds can efficiently deliver RNA to cells or tissues when forming lipid nanoparticles, showing strong transfection efficiency. The prepared lipid nanoparticles have good stability, and the encapsulation efficiency and particle size remain stable after long-term storage.

[0084] The ionizable sterol compounds of this disclosure not only serve as important lipid components for forming lipid nanoparticles, but in some embodiments, the ionizable sterol compounds themselves possess potent cancer cell differentiation and anti-cancer forms, exhibiting tumor suppression, chemoprevention, and neuroprotective properties. Therefore, the lipid carrier compositions or lipid nanoparticle compositions of this disclosure are expected to deliver active agents and provide dual efficacy for tumor suppression / chemoprevention / neuroprotection, offering superior options for targeted therapy and gene therapy.

[0085] Specifically, this disclosure provides the following ionizable sterol technical solution:

[0086] An ionizable sterol compound of formula A, or its stereoisomer, pharmaceutically acceptable salt or solvate,

[0087] Z-L-(M)r formula A

[0088] Wherein:

[0089] Z is the structure described in formula B below,

[0090]

[0091] Wherein, the wavy line indicates the connection point with L;

[0092] R1a is H, C1-6 alkyl, -C(O)NRaRb, -C(O)Rc, -C(O)ORd, or amino acid residue specification 9 / 41 page 22 CN 121378377 A Wherein Re is selected from the residue portion of L-histidine, L-leucine, L-isoleucine, L-valine, L-phenylalanine, L-tryptophan, L-lysine, L-tyrosine;

[0093] Ra and Rb may be the same as or different from each other, and are selected from H, -C1-6 alkyl, -C2-6 alkenyl and -C2-6 ynyl, each optionally substituted by one or more groups selected from allyl, carbonyl and 5- to 10-membered heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S,

[0094] Rc and Rd are each independently -C1-6 alkyl, -C2-6 alkenyl, or -C2-6 alkynyl;

[0095] R1b is H, -C1-6 alkyl, -C2-6 alkenyl, or -C2-6 alkynyl;

[0096] R2 is H, OH, or -OC1-6 alkyl;

[0097] R3 is H or CH3;

[0098] When W is a single bond with the carbon atom at the adjacent * position, W is selected from N and CRf, and R4 is H or OH; when W is a double bond with the carbon atom at the adjacent * position, W is C, and R4 is absent;

[0099] Rf is absent, H, halogen, or -C1-6 alkyl;

[0100] R5a and R5b are each independently H, OH, or -OC1-6 alkyl, or R5a and R5b together with the ring carbon atoms to which they are attached form -C(O)-;

[0101] L is a linker unit, which is a linear or branched alkylene group with optional substitutions having 3-50 skeletal carbon atoms, covalently linked to a steroidal ring segment and r ionizable head groups M, wherein at least one skeletal carbon atom of L is replaced by -O-, -S-, -NR6-, -NR6-NR6', -N=N-, -CH=N-, -N=CH-, -CH=CH-, -C≡C-, -O-NR6, -S-S-, -SO-, -SO2, -C(O)-, -C(=S)-, -C(=NR6)-, -C(O)O-, -C(O)S-, -OC(O)-, -SC(O)-, -NR6C(O)-, -C(O)NR6-, - NR6SO2-, -SO2NR6-, -OC(O)O-, -NR6C(O)O-, -OC(O)NR6-, -SC(O)NR6-, -NR6C(O)NR6'-, -NR6C (O)S-, -P(O)(OR6)O-, -OP(O)(OR6)-, -OP(O)(OR6)O-, optionally substituted C3-8 cycloalkylene, optionally substituted 3-8 heterocyclic alkylene, optionally substituted C6-10 arylene or optionally substituted 5-10 heterocyclic alkylene;

[0102] wherein R6 and R6' are each independently H, optionally substituted -C1-12 alkyl or optionally substituted -C2-12 alkenyl;

[0103] M is -(CH2)p-M1, wherein M1 is selected from NR7R8, optionally substituted saturated or partially unsaturated 3-8-membered heterocyclic groups containing at least one nitrogen atom, and optionally substituted 5-10-membered heteroaryl groups containing at least one nitrogen atom;

[0104] R7 and R8 are each independently selected from H, optionally substituted -C1-6 alkyl, optionally substituted -C2-6 alkenyl, and optionally substituted -C2-6 alkynyl;

[0105] G1 is absent, or

[0106] G2 is absent, or

[0107] G3 is absent, or

[0108] R11a and R11b are each independently H, -OH, or C1-6 alkyl; Specification10 / 41 Page 23 CN 121378377 A

[0109] R12 is selected from -C3-10 alkyl, -C3-10 alkenyl, -C3-10 cycloalkyl, -C3-10 cycloalkenyl, -C6-10 aryl, -3-8-membered heterocyclic group containing 1, 2 or 3 heteroatoms independently selected from N, O, S, 5-10-membered heteroaryl group containing 1, 2 or 3 heteroatoms independently selected from N, O, S, halogen, -OH, -OC3-10 alkyl, -NR13aR13b, wherein the cycloalkyl, aryl, heterocyclic and heteroaryl groups are each optionally substituted with -C1-6 alkyl;

[0110] R13a and R13b are each independently H or -C1-6 alkyl;

[0111] p is an integer from 0 to 6; and

[0112] q and r are each independently an integer from 1 to 3.

[0113] In one embodiment, the ionizable sterol compound of formula A is a compound of formula I, or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof,

[0114]

[0115] wherein:

[0116] L1 and L2 are each independently devoid of, or are straight-chain or branched-C1-12 alkylene groups, wherein the alkylene groups are optionally substituted with OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), -OC1-6 alkyl, -C1-6 alkyl, -C2-6 alkenyl, -C3-8 cycloalkyl, and wherein the alkylene groups are optionally substituted with one or more -O-, -S-, -NR6-, -CH= CH-, -C≡C-, -C(O)-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6--OC(O)NR6- or -OC(O)O- interval;

[0117] X is selected from non-existent, -O-, -S-, -NR6-, -NR6-NR6'-, -N=N-, -CH=N-, -N=CH-, -CH=CH-, -C≡C-, -O-NR6-, -S-S-, -SO-, -SO2, -C(O)-, -C(=S)-, -C(=NR6)-, -C(O)O-, -C(O)S-, -OC (O)-、-SC(O)-、-NR6C(O)-、-C(O)NR6-、-NR6SO2-、-SO2NR6-、-OC(O)O-、-NR6C(O)O-、-OC(O) NR6-、-SC(O)NR6-、-NR6C(O)NR6'-、-NR6C(O)S-、-P(O)(OR6)O-、-OP(O)(OR6)-、-OP(O)(OR6) O-、Optionally substituted C3-8 cycloalkylene groups、Optionally substituted 3-8 heterocyclic alkylene groups、Optionally substituted C6-10 arylene groups or optionally substituted C6-10 arylene groupsThe 5-10 membered heteroaryl group, wherein the optional substituent is selected from -OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), -OC1-6 alkyl, -C1-6 alkyl, -C2-6 alkenyl, -C3-8 cycloalkyl;

[0118] R6 and R6' are each independently H, -C1-12 alkyl or -C2-12 alkenyl, each optionally substituent from -OH, -COC1-6 alkyl, -COOC1-6 alkyl, -NH2, -NHC1-6 alkyl, -N(C1-6 alkyl)2, oxo, halogen, cyano, nitro, -C(O)NH2, -C(O) NHC1-6 alkyl, -C(O)N(C1-6 alkyl)2, -OC1-6 alkyl, -C1-6 alkyl, -C2-6 alkenyl, -C3-8 cycloalkyl;

[0119] M is -(CH2)p-M1, wherein M1 is selected from NR7R8, saturated or partially unsaturated 3-8 membered heterocyclic groups containing at least one nitrogen atom, 5-10 membered heteroaryl groups containing at least one nitrogen atom, wherein the heterocyclic group or heteroaryl group is optionally substituted with one or more OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), amidine, guanidinyl, -OC1-6 alkyl and -C1-6 alkyl;

[0120] R7 and R8 are each independently selected from H, -C1-6 alkyl, -C2-6 alkenyl, -C2-6 ynyl, and each is optionally substituted by one or more groups selected from the following: OH, -COR6, -COOR6, -NR6R6', -C(O)N(R6R6'), amidine, guanidinyl, halogen, cyano, nitro, -OC1-6 alkyl, -(OC1-6 alkylene)n-OH, saturated or partially unsaturated 3-8 membered heterocycles containing at least one nitrogen atom, or 5-10 membered heteroaryl groups containing at least one nitrogen atom, wherein the heterocyclic or heteroaryl group is optionally substituted by one or more OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), amidine, guanidinyl, -OC1-6 alkyl, and - C1-6 alkyl substitution;

[0121] n is an integer from 1 to 4;

[0122] The remaining groups are as defined in Formula A.

[0123] In a further embodiment, the compound of Formula I may have the following sub-general formula:

[0124] Specification 12 / 41 pages 25 CN 121378377 A

[0125]

[0126] wherein each group is as defined in Formula A and / or Formula I respectively.

[0127] In some embodiments of the above compounds, R1a is H and R1b is H.

[0128] In some embodiments of the above compounds, R1a is a -C1-6 alkyl, specifically a -C1-3 alkyl, such as methyl, ethyl, or propyl.

[0129] In some embodiments of the above compounds, R1a is -C(O)NRaRb, wherein Ra and Rb are the same as or different from each other, selected from H, -C1-6 alkyl, -C2-6 alkenyl, and -C2-6 ynyl, each optionally substituted by one or more groups selected from allyl, carbonyl, and 5 to 10 heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S; preferably Ra and Rb are the same as or different from each other, selected from H or optionally substituted by -C1-6 alkyl, -C2-6 alkenyl, and -C2-6 ynyl groups containing 1 to 3 heteroaryl groups selected from N, O, and S, such as 1H-imidazol-4-yl.

[0130] In some embodiments of the above compounds, R1a is -C(O)Rc, wherein Rc is -C1-6 alkyl, -C2-6 alkenyl or -C2-6 ynyl, preferably -C1-6 alkyl, more preferably -C1-3 alkyl, such as methyl, ethyl or propyl.

[0131] In some embodiments of the above compounds, R1a is -C(O)ORd, wherein Rd is -C1-6 alkyl, -C2-6 alkenyl or -C2-6 ynyl, preferably -C1-6 alkyl, such as ethyl or butyl.

[0132] In some embodiments of the above compounds, R1a is an amino acid residue, specifically wherein Re is selected from the residue portion of L-histidine, L-leucine, L-isoleucine, L-valine, L-phenylalanine, L-tryptophan, L-lysine, and L-tyrosine, specifically

[0133]

[0134] In some embodiments of the above compounds, R1a is selected from H, -C1-6 alkyl, and -C(O)C1-6 alkyl, preferably selected from H, -C1-3 alkyl, and -C(O)C1-3 alkyl.

[0135] In some embodiments of the above compounds, R1b is H.

[0136] In some embodiments of the above compounds, R1b is -C1-6 alkyl, -C2-6 alkenyl, or -C2-6 alkynyl.

[0137] In some embodiments of the above compounds, R2 is H.

[0138] In some embodiments of the above compounds, R2 is OH or -OC1-6 alkyl, for example, OH or -OC1-3 alkyl.

[0139] In some embodiments of the above compounds, R3 is CH3.

[0140] In some embodiments of the above compounds, W is N, in which case W is bonded to an adjacent carbon atom by a single bond, and R4 is H.

[0141] In some embodiments of the above compounds, W is -CRf, in which case W is bonded to an adjacent carbon atom by a single bond, R4 is H, and Rf is H.

[0142] In some embodiments of the above compounds, W is -CRf, where W is a single bond with the adjacent carbon atom, R4 is OH, and Rf is H; further, the configuration of the ring carbon atom to which R4 is attached is S configuration.

[0143] In some embodiments of the above compounds, W is -CRf, where W is a double bond with the adjacent carbon atom, R4 is absent, and Rf is absent.

[0144] In some embodiments of the above compounds, R5a and R5b are each independently H.

[0145] In some embodiments of the above compounds, R5a and R5b are each independently H, OH, or -OC1-6 alkyl.

[0146] In some embodiments of the above compounds, R5a and R5b together with the ring carbon atom to which they are attached form -C(O)-.

[0147] In some embodiments of the above compounds, L is a linking unit, which is a straight-chain or branched alkylene with 3-50 skeletal carbon atoms, covalently linked to a steroidal segment and r ionizable head groups M; specifically, it is a straight-chain or branched alkylene with 3-40, 3-30, or 3-20 skeletal carbon atoms, more specifically, a straight-chain or branched alkylene with 2-12 skeletal carbon atoms.

[0148] In some embodiments of the above compounds, at least one skeletal carbon atom of L is converted to -O-, -S-, -NR6-, -NR6-NR6', -N=N-, -CH=N-, -N=CH-, -CH=CH-, -C≡C-, -O-NR6, -S-S-, -SO-, -SO2, -C(O)-, -C(=S)-, -C(=NR6)-, -C(O)O-, -C(O)S-, -OC(O)-, -SC(O)-, -NR6C(O)-, -C(O)NR6-, -NR6SO2-, -SO2NR6-, -OC(O)O-, -NR6C(O)O-, -OC(O)NR6-, -SC(O)NR6-, -NR6C(O)NR6'-, -NR6C (O)S-, -P(O)(OR6)O-, -OP(O)(OR6)-, -OP(O)(OR6)O-, optionally substituted C3-8 cycloalkylene, optionally substituted 3-8 heterocyclic alkylene, optionally substituted C6-10 arylene or optionally substituted 5-10 heterocyclic alkylene;

[0149] Specifically, at least one skeletal carbon atom is replaced by -O-, -S-, -NR6-, -NR6-NR6', -S-S-, -SO-, -SO2, -CH=CH-, -C≡C-, -C(O)-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6-, -NR6SO2-, -SO2NR6-, -OC(O)O-, -NR6C(O)O-, -OC(O)NR6-, -NR6C(O)NR6'-, optionally substituted C3-6 cycloalkylene, optionally substituted 5-7 heterocyclic, optionally substituted C6-10 arylene or optionally substituted 5-10 heterocyclic;

[0150] More specifically, at least one skeletal carbon atom of L is replaced by -O-, -S-, -NR6-, -S-S-, -SO-, -SO2, -CH=CH-, -C≡C-, -C(O)-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6-, -OC(O)O-, -NR6C(O)O-, -OC(O)NR6-, -NR6C(O)NR6'-.

[0151] In some embodiments of the above compounds, the optional substituents on L are selected from OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), -OC1-6 alkyl, -C1-6 alkyl, -C2-6 alkenyl, -C3-8 cycloalkyl; specifically selected from OH, -NR6R6', halogen, -OC1-6 alkyl, -C2-6 alkenyl, -C3-6 cycloalkyl.

[0152] In some embodiments of the above compounds, given that the linking unit L itself can be a branched structure, and that its skeletal atoms or the substituted segments can carry substituted or unsubstituted amino groups, the ionizable sterol compounds of this disclosure can carry two or more ionizable sites.

[0153] In some embodiments, the linker unit L comprises a branched alkylene group, each branch of which can be linked to an M group as defined herein, for example, having two branches and carrying at least two M groups, having three branches and carrying at least three M groups.

[0154] In some embodiments, the alkylene group of the linker unit L is a straight-chain alkylene group, thereby the compound comprises a structural segment specifically

[0155] In some embodiments, the alkylene group of the linker unit L has two branches at its end, thereby the compound comprises a structural segment specifically wherein each p and M1 takes an independent value.

[0156] In some embodiments, the alkylene group of the linker unit L has three branches at its end, thereby the compound comprises a structural segment specifically wherein each p and M1 takes an independent value.

[0157] In some embodiments of the above compounds, L is -L1-X-L2-, wherein when X is absent, L1 and L2 are present at least one of them.

[0158] In some embodiments of the above compounds, L is -L1-X-L2-, wherein when L1 is absent, at least one of X and L2 is present.

[0159] In some embodiments of the above compounds, L is -L1-X-L2-, wherein p is not 0 when L2 is absent.

[0160] In some embodiments of the above compounds, L is -L1-X-L2-, wherein L1 and / or L2 are each independently absent, or are straight-chain or branched -C1-12 alkylene-, specifically straight-chain or branched -C1-6 alkylene-.

[0161] In some embodiments, L1 and / or L2 are straight-chain -C1-12 alkylene-, with optional substituents and spacers as defined herein in general, specific, or preferred embodiments.

[0162] In some embodiments, L1 and / or L2 are branched -C1-12 alkylene-, with optional substituents and spacers as defined herein in general, specific, or preferred embodiments.

[0163] In some embodiments of the above compounds, the alkylene groups in L1 and / or L2 may optionally be substituted with -OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), -OC1-6 alkyl, -C1-6 alkyl, -C2-6 alkenyl, -C3-8 cycloalkyl, specifically with -OH, -NR6R6', halogen, -OC1-6 alkyl, -C2-6 alkenyl, -C3-6 cycloalkyl, and more specifically with -OH, -NR6R6', halogen, -OC1-6 alkyl.

[0164] In some embodiments of the above compounds, the alkylene groups in L1 and / or L2 are optionally separated by one or more -O-, -S-, -NR6-, -CH=CH-, -C≡C-, -C(O)-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6-, -OC(O)NR6-, -NR6C(O)O-, -NR6C(O)NR6'- or -OC(O)O-, specifically optionally separated by one or more -O-, -NR6-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6-, -NR6C(O)O-, -NR6C(O)NR6'-, -OC(O)NR6- or -OC(O)O-.

[0165] In some embodiments, the alkylene groups of L1 and / or L2 are optionally separated by one or more -O-, for example, L1 and / or L2 contain repeating structural segments -[(CH2)m-O]t-, where m is an integer from 1 to 6 and t is an integer from 0 to 6; in one specific embodiment, m is an integer from 2 and t is an integer from 2 to 6; in another specific embodiment, m is an integer from 1 to 6 and t is 1; it should be noted that each repetition of -[(CH2)m-O]- is independently an integer from 1 to 6.

[0166] In some embodiments, the alkylene groups of L1 and / or L2 are optionally separated by one or more -NR6-, for example, L1 and / or L2 contain repeating structural segments -[(CH2)m-O]t-, where m is an integer from 1 to 6.Or L2 contains a repeating structural fragment -[(CH2)m-NR6]t-, where m is an integer from 1 to 6 and t is an integer from 0 to 6; in one specific embodiment, m is an integer from 2 to 4 and t is an integer from 2 to 6; in another specific embodiment, m is an integer from 1 to 6 and t is 1; it should be noted that each repetition of -[(CH2)m-NR6]- in each instance is independently an integer from 1 to 6.

[0167] In some embodiments, the alkylene groups of L1 and / or L2 are separated by one or more -NR6C(O)O-, -NR6C(O)NR6'-, -OC(O)NR6- or -OC(O)O-; for example, -C1-6 alkylene-O-CO-NR6-C1-6 alkylene-, -C1-6 alkylene-O-CO-O-C1-6 alkylene-.

[0168] In some embodiments of the above compounds, L1 is absent, or is -C1-6 alkylene- or -C2-6 alkenyl-.

[0169] In some embodiments of the above compounds, X is absent.

[0170] In some embodiments of the above compounds, X is selected from -O-, -S-, -NR6-, -NR6-NR6', -N=N-, -CH=N-, -N=CH-, -O-NR6, -S-S-, -SO-, -SO2, -C(O)-, -C(=S)-, -C(=NR6)-, -C(O)O-, -C(O)S-, -OC(O)-, -SC(O)-, -NR6C(O)-, -C(O)NR6-, -NR6SO2-, -SO2NR6-, -OC(O)O-, -NR6C(O)O-, -OC(O) NR6-, -SC(O)NR6-, -NR6C(O)NR6'-, -NR6C(O)S-, -P(O)(OR6)O-, -OP(O)(OR6)-, -OP(O)(OR6)O-, optionally substituted C3-8 cycloalkylene, optionally substituted 3-8 heterocyclic alkylene, optionally substituted C6-10 arylene or optionally substituted 5-10 heterocyclic alkylene, wherein the optional substituent is selected from OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), -OC1-6 alkyl, -C1-6 alkyl, -C2-6 alkenyl, -C3-8 cycloalkyl; Specification 16 / 41 pages 29 CN 121378377 A

[0171] Specifically, (O)‑,‑C(O)O‑,‑OC(O)‑,‑NR6C(O)‑,‑C(O)NR6‑,‑NR6SO2‑,‑SO2NR6‑,‑OC(O)O‑,‑NR6C(O)O-, -OC(O)NR6-, -NR6C(O)NR6'-, optionally substituted C3-6 cycloalkylene, optionally substituted 5-7 heterocyclic alkylene, optionally substituted C6-10 arylene or optionally substituted 5-10 heterocyclic alkylene;

[0172] More specifically, X is selected from -O-, -S-, -NR6-, -S-S-, -SO-, -SO2, -CH=CH-, -C≡C-, -C(O)-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6-, -OC(O)O-, -NR6C(O)O-, -OC(O)NR6-, -NR6C(O)NR6'-;

[0173] More specifically, X is selected from -O-, -S-, -NR6-, -NR6-NR6'-, -O-NR6-, -C(O)-, -C(O)O-, -OC (O)-, -NR6C(O)-, -C(O)NR6-, -OC(O)O-, -NR6C(O)O-, -OC(O)NR6-, -NR6C(O)NR6'-;

[0174] More specifically, X is selected from -O-, -NR6-, -OC(O)-, -NR6C(O)-, -OC(O)O-, -NR6C(O)O-, -OC(O)NR6-, -NR6C(O)NR6'-.

[0175] In some embodiments of the above compounds, the optional substituents on X are selected from OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)NR6, -OC1-6 alkyl, -C1-6 alkyl, -C2-6 alkenyl, -C3-8 cycloalkyl; specifically selected from OH, -NR6R6', halogen, -OC1-6 alkyl, -C2-6 alkenyl, -C3-6 cycloalkyl.

[0176] In some embodiments of the above compounds, M is -(CH2)p-M1, wherein M1 is NR7R8.

[0177] In some embodiments of the above compounds, R7 and R8 are each independently selected from H, optional substituted -C1-6 alkyl, optional substituted -C2-6 alkenyl, optional substituted -C2-6 ynyl; specifically selected from H and optional substituted -C1-6 alkyl.

[0178] In some embodiments of the above compounds, the -C1-6 alkyl, -C2-6 alkenyl, and -C2-6 alkynyl groups in R7 and R8 are each optionally substituted with one or more groups selected from the following: -OH, -COR6, -COOR6, -NR6R6', -C(O)N(R6R6'), amidine, guanidinyl, halogen, cyano, nitro, -OC1-6 alkyl, -(OC1-6 alkylene)n-OH, saturated or partially unsaturated 3-8 membered heterocyclic groups containing at least one nitrogen atom, and 5-10 membered heteroaryl groups containing at least one nitrogen atom, wherein the heterocyclic or heteroaryl group is optionally substituted with the following:The substituents on R7 and R8 are selected from one or more OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), amido, guanidino, -OC1-6alkyl, and -C1-6alkyl.

[0179] In some embodiments of the above compounds, the optional substituents on R7 and R8 are selected from -OH, -COOR6, -NR6R6', halogen, cyano, nitro, -OC1-6alkyl, saturated or partially unsaturated 4-7 membered heterocyclic groups containing at least one nitrogen atom, and 5-10 membered heteroaryl groups containing at least one nitrogen atom, wherein the heterocyclic or heteroaryl group is optionally substituted with one or more OH, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -OC1-6alkyl, and C1-6alkyl.

[0180] In some embodiments of the above compounds, the optional substituents on R7 and R8 are selected from -OH and -NR6R6'.

[0181] In some embodiments of the above compounds, M is -(CH2)p-M1, wherein M1 is NR7R8, R7 and R8 are each independently selected from H and optionally substituted -C1-6 alkyl, such as -NH2, -NHC1-6 alkyl, -N(C1-6 alkyl)2, wherein the alkyl is optionally substituted by one or more -OH, -COOH, -NR6R6', oxo, halogen, cyano, nitro, -OC1-6 alkyl, specifically optionally substituted by one or more -OH and / or -NR6R6'.

[0182] In some embodiments of the above compounds, M is -(CH2)p-NH2.

[0183] In some embodiments of the above compounds, M is -(CH2)p-M1, wherein M1 is -NHC1-6 alkyl or -N(C1-6 alkyl)2, wherein the alkyl group is optionally substituted by one or more -OH and / or -NR6R6', wherein R6 and R6' are each independently H or -C1-6 alkyl group optionally substituted by -OH; for example, M is: Specification 17 / 41 pages 30 CN 121378377 A

[0184] and a corresponding fragment in which each terminal alkyl group is substituted by -OH.

[0185] In some embodiments of the above compounds, M is -(CH2)p-M1, wherein M1 is an optionally substituted saturated or partially unsaturated 3-8-membered heterocyclic group containing at least one nitrogen atom, specifically an optionally substituted saturated or partially unsaturated 4-7-membered heterocyclic group containing at least one nitrogen atom, for example, but not limited to, each optionally substituted by one or more OH, -COOH, -NH2, oxo, halogen, cyano, nitro, -OC1-6 alkyl, and C1-6 alkyl.

[0186] In some embodiments of the above compounds, M is -(CH2)p-M1, wherein M1 is an optionally substituted 5-10-membered heteroaryl group containing at least one nitrogen atom, specifically a 5-6-membered heteroaryl group, for example, but not limited to,The substituted compound may be optionally substituted with one or more OH, -COOH, -NH2, oxo, halogen, cyano, nitro, -OC1-6 alkyl, and C1-6 alkyl.

[0187] In some embodiments of the above compounds, M is -(CH2)p-M1, specifically M is M1, wherein M1 is selected from -NH2, -NH2-C1-6 alkyl, -N(C1-6 alkyl)2, wherein the -C1-6 alkyl, heterocyclic, or heteroaryl group is optionally substituted with one or more OH, -COOH, -NH2, oxo, halogen, cyano, nitro, -OC1-6 alkyl, and C1-6 alkyl groups.

[0188] In some embodiments of the above compounds, R6 and R6' are each independently H.

[0189] In some embodiments of the above compounds, R6 and R6' are each independently an optionally substituted -C1-12 alkyl group; specifically, an optionally substituted -C1-6 alkyl group.

[0190] In some embodiments of the above compounds, the substituents of R6 and R6' are selected from -OH, -NH2, -NHC1-6 alkyl, -N (C1-6 alkyl)2; preferably, the substituent is -OH.

[0191] In some embodiments of the above compounds, L1 is absent, and / or X is selected from -O-, -S-, -NR6-, -NR6-NR6', -N=N-, -CH=N-, -N=CH-, -CH=CH-, -C≡C-, -O-NR6, -S-S-, -SO-, -SO2, -C(O)-, -C(=S)-, -C(=NR6)-, -C(O)O-, -C(O)S-, -OC(O)-, -SC(O)-, -NR6C(O)-, -C(O)NR6-, -NR6SO2-, -SO2NR6-, -OC(O)O-, -NR6C(O)O-, -OC(O)NR6-, -SC(O)NR6-, -NR6C(O)NR6'-, -NR6C (O)S-, -P(O)(OR6)O-, -OP(O)(OR6)-, -OP(O)(OR6)O-, and / or L2 is a straight-chain or branched -C1-12 alkylene- as defined herein, specifically a straight-chain or branched -C1-6 alkylene-, with optional substituents and spacers as defined herein in general or specific or preferred embodiments, and R6 and R6', M each as defined herein in general or specific or preferred embodiments;

[0192] Specifically, in these embodiments, L1 is absent; and / or

[0193] X is selected from -O-, -S-, -NR6-, -NR6-NR6'-, -O-NR6-, -C(O)-, -C(O)O-, -OC(O)-, -NR6C(O)-、-C(O)NR6-、-OC(O)O-、-NR6C(O)O-、-OC(O)NR6-、-NR6C(O)NR6'-;Preferably X is selected from -O-、-NR6-、-OC(O)-、-NR6C(O)-、-OC(O)O-、-NR6C(O)O-、-OC(O)NR6-、-NR6C(O)NR6'-;and / /

[0194] L2 is a straight-chain or branched -C1-12 alkylene group, optionally substituted with -OH、-NR6R6'、halogen、-OC1-6 alkyl, and optionally substituted with one or more -O-、-NR6-、-C(O)O-、-OC(O)-、-NR6C(O)-、-C(O)NR6-、-NR6C(O)O-、-NR6C(O)O-、-NR6C(O) NR6'-, -OC(O)O-, or -OC(O)NR6- are spaced apart; and

[0195] wherein R6 and R6' are each independently H, -C1-6 alkyl, or -C2-6 alkenyl; preferably each independently H or -C1-6 alkyl, optionally substituted with -OH, -NH2, -NHC1-6 alkyl, -N(C1-6 alkyl)2, preferably optionally substituted with -OH;

[0196] More specifically, in these embodiments, the alkylene of L2 is a straight-chain alkylene, thereby the compound contains a structural segment, or the alkylene terminus of L2 has two branches, thereby the compound contains a structural segment, or the alkylene terminus of L2 has three branches, thereby the compound contains a structural segment, wherein p is an integer from 0 to 6, for example, an integer from 1 to 4 or 1 to 3, and M1 is as defined herein in general, specific or preferred embodiments, preferably M1 is -NHC1-6 alkyl or -N(C1-6 alkyl)2, wherein the alkyl is substituted by one or more -OH and / or -NR6R6', wherein R6 and R6' are each independently H or optionally -C1-6 alkyl substituted by -OH, as exemplified above.

[0197] In some embodiments of the above compounds, the linker L or -L1-X-L2- may have structures including but not limited to the following: Specification 19 / 41 page 32 CN 121378377 A

[0198] Specification 20 / 41 page 33 CN 121378377 A

[0199]

[0200] Wherein, the asterisk indicates the connection point with the steroidal ring segment, the wavy line appearing alone indicates the connection point with M, when there are multiple wavy lines, at least one indicates the connection point with M, and the rest indicate the connection point with the alkyl branch of H or L2, m is an integer from 1 to 6, and t is an integer from 0 to 6; in one specific embodiment, m is an integer from 2 to 4, and t is an integer from 2 to 6; in another specific embodiment, m is an integer from 1 to 6, and t is 1; it should be noted that each repeated -[(CH2)m-NR6]- or -In [(CH2)m-O], each m is an integer from 1 to 6.

[0201] It should be noted that the compounds disclosed herein may contain linking units formed by any combination of the components in the above-described linking units, in general or in specific or preferred terms, and further cover -L-(M)r fragments formed by any combination of these linking units and any M in the above-described general or in specific or preferred terms, as long as it is chemically feasible.

[0202] In some embodiments of the above compounds, G1 is absent, or G2 is absent, or G3 is absent;

[0203] R11a and R11b are each independently H or C1-6 alkyl, specifically one is H and the other is -CH3;

[0204] R12 is selected from -C3-10 cycloalkyl, -C3-10 cycloalkenyl, -C6-10 aryl, -3-8-membered heterocyclic group containing 1, 2 or 3 heteroatoms independently selected from N, O, S, and 5-10-membered heteroaryl group containing 1, 2 or 3 heteroatoms independently selected from N, O, S, wherein the cycloalkyl, aryl, heterocyclic and heteroaryl groups are each optionally substituted with -C1-6 alkyl;

[0205] In specific embodiments, the optional substituents on R12 may be selected from

[0206] In some embodiments of the above compounds, -G1-G2-G3-R12 is wherein R11a is H or C1-6 alkyl, preferably H or C1-3 alkyl.

[0207] In some embodiments of the above compounds, -G1-G2-G3-R12 is wherein R11a is H or C1-6 alkyl, R12 is selected from - 3-8 membered heterocyclic groups containing 1, 2 or 3 heteroatoms independently selected from N, O, S, -OH, -OC3-10 alkyl, -NR13aR13b, wherein the heterocyclic group is optionally substituted with -C1-6 alkyl.

[0208] In some embodiments of the above compounds, -G1-G2-G3-R12 is wherein R11a is H or C1-6 alkyl, R14a is C1-6 alkyl, and R14b is selected from H or C1-6 alkyl. Specification 22 / 41 pages 35 CN 121378377 A

[0209] In some embodiments of the above compounds, -G1-G2-G3-R12 is wherein R11a is H or C1-6 alkyl, and R15 is selected from halogen, OH, or C1-6 alkyl.

[0210] In some embodiments of the above compounds, -G1-G2-G3-R12 is wherein R11a is H or C1-6 alkyl, and R16a and R16b are selected from C1-6 alkyl.

[0211] In some embodiments of the above compounds, -G1-G2-G3-R12 is wherein R11a is H or C1-6 alkyl, and R17a and R17b are each independently selected from H, OH, or C1-6 alkyl.

[0212] In some embodiments of the above compounds, -G1-G2-G3-R12 is wherein R11a is H or C1-6 alkyl, and R18a, R18b and R18c are each C1-6 alkyl.

[0213] In some embodiments of the above compounds, -G1-G2-G3-R12 is wherein R19a is selected from H, -C1-6 alkyl or =CH-C1-6 alkyl, and R19b and R19c are each C1-6 alkyl.

[0214] In some embodiments of the above compounds, especially in the -G1-G2-G3-R12 scheme, R11a is selected from H and specification page 23 / 41 36 CN 121378377 A

[0215] Preferably

[0216] In some embodiments of the above compounds, especially in the -G1-G2-G3-R12 scheme, R14a, R14b, R15, R16a, R16b, R17a, R17b, R18a, R18b, R18c, R19b, R19c can be selected from C1-6 alkyl when they are taken from

[0217] In some embodiments of the above compounds, G1 is wherein one of R11a and R11b is H, and the other is C1-3 alkyl, preferably methyl; G2 is wherein q is 2; G3 is absent; and R12 is selected from - C3-10 alkyl and -C3-10 alkenyl, preferably -C3-6 alkyl and -C3-6 alkenyl, more preferably -C4-6 alkyl and -C4-6 alkenyl; wherein the alkyl or alkenyl group is preferably branched;

[0218] Specifically, R12 has the following formula: wherein R12a is selected from H, -CH3, -CH2CH3, =CHCH3.

[0219] It should be noted that the compounds disclosed herein may comprise Z fragments formed by any combination of the general or specific or preferred definitions of the various components of the Z fragments above, and further cover ionizable sterol compounds formed by any combination of these Z fragments with the linking unit as generally or specifically or preferably defined above, and any M as generally or specifically or preferably defined above, as per the description of the chemical specification 24 / 41 pages 37 CN 121378377 A.

[0220] In some embodiments of the above compounds, Z is, for example, but not limited to, the following fragments:

[0221]

[0222]

[0223] and wherein the hydroxyl group at the 3-position of the steroid ring is a corresponding fragment of -O-R1a as defined herein, preferably wherein R1a is a corresponding fragment of H, -C1-6 alkyl, and -C(O)C1-6 alkyl.

[0224] In some embodiments of the above compounds, wherein the ionizable sterol compound is, for example, but not limited to, the following compounds: Specification 25 / 41 pages 38 CN 121378377 A

[0225] Specification 26 / 41 pages 39 CN 121378377 A

[0226]

[0227] Wherein R1a is defined as generally, specifically, or preferably as described above, specifically as H, -C1-6 alkyl or C1-6 alkyl-CO-, such as CH3CO-, C2H5CO-, C3H7CO-, -C2H5, -C3H7,

[0228] or its stereoisomers, pharmaceutically acceptable salts or solvates.

[0229] In some embodiments, the ionizable sterol compounds do not include

[0230] 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-propionate;

[0231] 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-hexanoate;

[0232] 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl-ethyl carbonate;

[0233] 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl-butyl carbonate;

[0234] 5α-Hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl-1-H-imidazol-4-yl ethylcarbamate;

[0235] 5α-Hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl ethylcarbamate;

[0236] L-Histidine 5α-Hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl ester; Specification 27 / 41 pages 40 CN 121378377 A

[0237] L-Leucine 5α-Hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl ester;

[0238] L-Isoleucine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl ester;

[0239] L-Valine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl ester;

[0240] L-Phenylalanine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl ester;

[0241] L-Tryptophan 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl ester;

[0242] L-Lysine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestane-3β-yl ester;

[0243] L-Tyrosine 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl ester; and

[0244] L-proline 5α-hydroxy-6β-[2-(1H-imidazol-4-yl)-ethylamino]-cholestan-3β-yl ester.

[0245] It should be noted that this disclosure covers compound solutions formed by any combination of general or specific structural fragments defined in the above embodiments.

[0246] II. Lipid Carrier Composition or Bioactive Substance Delivery System

[0247] The ionizable sterol compounds or stereoisomers thereof, pharmaceutically acceptable salts or solvates of this disclosure can complex nucleic acid molecules to form stable lipid nanoparticle structures, which advantageously promote the delivery and transfection of nucleic acids and have the ability to specifically target organ tissues, and can therefore be used to prepare delivery carriers or delivery systems for nucleic acid drugs. The delivery system can also be advantageously used to deliver other therapeutic agents and / or prophylactic agents.

[0248] This disclosure thereby provides a lipid carrier composition or bioactive substance delivery system comprising the ionizable sterol compounds or stereoisomers thereof of this disclosure, pharmaceutically acceptable salts or solvates.

[0249] In a further embodiment, the lipid carrier composition or bioactive substance delivery system of this disclosure further comprises phospholipids, (optionally) structural lipids, and polymer-conjugated lipids. In specific embodiments, the lipid carrier composition or bioactive substance delivery system of this disclosure may be in the form of lipid nanoparticles, liposomes, microvesicles, microparticles, nanoparticles, and lipid complexes. In more specific embodiments, the lipid carrier composition or bioactive substance delivery system of this disclosure is in the form of lipid nanoparticles.

[0250] The lipid carrier composition or bioactive substance delivery system of this disclosure can efficiently deliver bioactive substances to cells, tissues, and organs, achieving efficient regulation of bioactive substances. The bioactive substances may be therapeutic agents, diagnostic agents, or preventive agents, and may be in the form of nucleic acids, small molecule compounds, proteins, or peptides, and may be in liquid, gas, or solid form.

[0251] In some embodiments of this disclosure, the lipid carrier composition or bioactive substance delivery system comprises a selection from the specific ionizable sterol compounds shown above, such as the following ionizable sterol compounds 1 to 8: Specification 28 / 41 pages 41 CN 121378377 A

[0252]

[0253] or their stereoisomers, pharmaceutically acceptable salts, or solvates.

[0254] For embodiments of the lipid carrier composition or bioactive substance delivery system of this disclosure, the molar percentage of the ionizable sterol compound contained therein to the total lipids may be about 15% to about 70%, about 15% to about 65%, about 15% to about 6%, about 15% to about 55%, about 20% to about 70%, about 20% to about 65%, about 20% to about 60%, about 20% to about 55%, about 30% to about 70%, about 30% to about 60%, about 30% to about 55%, about 40% to about 70%, about 40% to about 65%, about 40% to about 60%, about 40% to about 55%, preferably about 30% to about 60%, more preferably about 40% to about 55%.Approximately 60%, most preferably approximately 50%.

[0255] For embodiments of the lipid carrier composition or bioactive substance delivery system disclosed herein, the phospholipids contained herein include, but are not limited to, phosphatidylcholine compounds and / or phosphatidylethanolamine compounds, and may also be phosphatidylserine, phosphatidylinositol, phosphatidic acid, etc. For example, but not limited to:

[0256] 1,2-Dilinoleoyl-sn-glycerol-3-phosphate choline (DLPC),

[0257] 1,2-Dimyristoyl-sn-glycerol-3-phosphate choline (DMPC),

[0258] 1,2-Dioleoyl-sn-glycerol-3-phosphate choline (DOPC),

[0259] 1,2-Dipalmitoyl-sn-glycerol-3-phosphate choline (DPPC),

[0260] 1,2-distearateoyl-sn-glycerol-3-phosphate choline (DSPC), Specification 29 / 41 pages 42 CN 121378377 A

[0261] 1,2-Di-undecanoyl-sn-glycerol-3-phosphate choline (DUPC),

[0262] 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate choline (POPC),

[0263] 1,2-Di-O-octadecenyl-sn-glycerol-3-phosphate choline (18:O diether PC),

[0264] 1-Oleoyl-2-cholesterolyl hemisuccinyl-sn-glycerol-3-phosphate choline (OChemsPC),

[0265] 1-Hexadecyl-sn-glycerol-3-phosphate choline (C16 Lyso PC),

[0266] 1,2-Divinyl-sn-glycerol-3-phosphate choline,

[0267] 1,2-Diarylyl-sn-glycerol-3-phosphate choline,

[0268] 1,2-Dilinoleoyl-sn-glycerol-3-phosphate choline,

[0269] 1,2-Diarachidonicoyl-sn-glycerol-3-phosphate choline,

[0270] 1,2-bis(docosahexaenoicoyl)-sn-glycerol-3-phosphate choline,

[0271] 1,2-Dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE),

[0272] 1,2-Diphyranoyl-sn-glycerol-3-phosphate ethanolamine (ME 16.0PE),

[0273] 1,2-distearate-sn-glycerol-3-phosphate ethanolamine,

[0274] 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine,

[0275] 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine,

[0276] 1,2-disarachidonicoyl-sn-glycerol-3-phosphate ethanolamine,

[0277] 1,2-divinyl-sn-glycerol-3-phosphate ethanolamine,

[0278] 1,2-divinyl-sn-glycerol-3-phosphate ethanolamine,

[0279] 1,2-diaryl-sn-glycerol-3-phosphate ethanolamine,

[0280] 1,2-Dithiohexaenoic acid-sn-glycerol-3-phosphate ethanolamine,

[0281] 1,2-bis(docosahexaenoic acid-sn-glycerol-3-phosphate ethanolamine,

[0282] 1,2-dioleoyl-sn-glycerol-3-phosphate-rac-(1-glycerol) sodium salt (DOPG),

[0283] dipalmitoylphosphatidylglycerol (DPPG),

[0284] palmitoyloleoylphosphatidylethanolamine (POPE),

[0285] distearate-phosphatidyl-ethanolamine (DSPE),

[0286] dipalmitoylphosphatidylethanolamine (DPPE),

[0287] dimyristoylphosphatidylethanolamine (DMPE),

[0288] 1-stearoyl-2-oleoylphosphatidylethanolamine (SOPE),

[0289] 1-Stearyl-2-oleoyl-phosphatidylcholine (SOPC),

[0290] sphingomyelin and mixtures thereof.

[0291] Preferably, for embodiments of the lipid carrier composition or bioactive substance delivery system of this disclosure, the phospholipid contained therein is selected from DSPC, DSPE, DOPE, DMPE, DMPC. In another embodiment, the phospholipid is selected from DSPC, DOPE or a combination thereof. In another embodiment, the phospholipid is DSPC.

[0292] For embodiments of the lipid carrier composition or bioactive substance delivery system of the present disclosure, the molar percentage of phospholipids contained therein to the total lipids may be about 0% to about 40%, about 0% to about 30%, about 0% to about 25%, about 0% to about 20%, about 0% to about 15%, about 5% to about 40%, about 5% to about 30%, about 5% to about 25%, about 5% to about 20%, about 5% to about 15%, about 10% to about 40%, about 10% to about 30%, about 10% to about 25%, about 10% to about 20%, about 10% to about 15%, preferably about 5% to about 20%, more preferably about 5% to about 15% or about 10% to about 15%, and most preferably about 10%. Specification page 30 / 41 43 CN 121378377 A

[0293] For embodiments of the lipid carrier composition or bioactive substance delivery system of this disclosure, the structural lipids contained therein may include steroids or sterols, including but not limited to one or more of cholesterol, cod sterol, sitosterol, ergosterol, stigmasterol, or derivatives thereof with equivalent properties, such as cholesterol succinate. In one embodiment, the structural lipid is cholesterol.

[0294] For embodiments of the lipid carrier composition or bioactive substance delivery system of this disclosure, the molar percentage of the structural lipid, such as cholesterol, in the total lipids may be from about 0 to about 60%, from about 0 to about 50%, from about 0 to about 40%, etc.About 20% to about 60%, about 20% to about 55%, about 20% to about 50%, about 20% to about 45%, about 25% to about 60%, about 25% to about 55%, about 25% to about 50%, about 25% to about 45%, about 30% to about 60%, about 30% to about 50%, about 35% to about 60%, about 35% to about 50%, about 35% to about 45%, preferably about 20% to about 50%, about 25% to about 50%, more preferably about 35% to about 50%.

[0295] For embodiments of the lipid carrier composition or bioactive substance delivery system of this disclosure, the polymer-conjugated lipid contained therein is a PEG lipid, comprising a lipid portion and a PEG-based polymer portion. The lipid portion includes, for example, one or more of phosphatidylethanolamine, phosphatidic acid, ceramide, dialkylamine, diacylglycerol, diacylglycerol amide, and dialkylglycerol. The PEG polymer portion can be a copolymer, such as PEG-polyurethane or PEG-polypropylene, or it can be a PEG monomer. The molecular weight of the PEG portion is 100–50,000, preferably 200–10,000, more preferably 500–3,000, and most preferably 1,500–2,500. In some embodiments, the PEG is PEG2000, with an average molecular weight of about 2,000 Daltons.

[0296] In some embodiments, the PEG lipid molecule may be selected from, but is not limited to: 1,2-dimyristoyl-sn-glycerol methoxy polyethylene glycol (PEG-DMG), 1,2-distearate-sn-glycerol-3-phosphate ethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-distearate glycerol (PEG-DSG), PEG-dipalmitoyl, PEG-dioleoyl, PEG-distearate, PEG-diacylglycineamide (PEG-DAG), PEG-dispalmitoylphosphatidylethanolamine (PEG-DPPE) or PEG-1,2-dimyristoyloxypropyl-3-amine (PEG-c-DMA).

[0297] In one embodiment, the PEG lipid is selected from 1,2-dimyristoyl-sn-glycerol methoxy polyethylene glycol (PEG-DMG) or 1,2-distearyl-sn-glycerol-3-phosphate ethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE). In one embodiment, the PEG lipid is selected from 1,2-dimyristoyl-sn-glycerol methoxy polyethylene glycol 2000 (PEG2000-DMG) or 1,2-distearyl-sn-glycerol-3-phosphate ethanolamine-N-[amino(polyethylene glycol)-2000] (PEG2000-DSPE).

[0298] For embodiments of the lipid carrier composition or bioactive substance delivery system of this disclosure, wherein the included...The molar percentage of PEG lipids in the total lipids may be from about 0.5% to about 10%, from about 0.5% to about 5%, from about 0.5% to about 2.5%, from about 1% to about 10%, from about 1% to about 5%, from about 1% to about 3%, from about 1% to about 2.5%, or from about 1% to about 2%; preferably from about 1% to about 5%, from about 0.5% to about 2.5%, and more preferably from about 1% to about 2%.

[0299] In some embodiments, the ionizable sterol compound included in the lipid carrier composition or bioactive substance delivery system is selected from ionizable sterol compounds as defined herein, such as ionizable sterol compounds 1-8, for example, the included phospholipid is selected from DSPC, DOPE or a combination thereof, the included structural lipid is cholesterol, and the included polymer-conjugated lipid is PEG-DMG and / or PEG-DSPE, specifically PEG2000-DMG and / or PEG2000-DSPE.

[0300] In some embodiments, the molar ratio of the ionizable sterol compound, phospholipid, structural lipid, and polymer-conjugated lipid is 15–70:0–30:20–60:0.5–10, for example 20–60:5–30:20–50:0.5–5, 30–60:5–20:25–50:1–5, 40–60:5–15:30–50:1–2.

[0301] In some embodiments, the molar ratio of the ionizable sterol compound, phospholipid, structural lipid, and polymer-conjugated lipid is 50:10:38.5:1.5.

[0302] Since the sterol compound of this disclosure contains both an ionizable cationic lipid component and a sterol component, it can act as both an ionizable lipid and a structural lipid, thereby enabling a three-component lipid carrier composition or bioactive substance delivery system. Therefore, in some embodiments, the ionizable sterol compound contained in the lipid carrier composition or bioactive substance delivery system is selected from the ionizable sterol compounds 1-8 as defined in this disclosure, for example, the phospholipid contained is selected from DSPC, DOPE or a combination thereof, and the polymer-conjugated lipid contained is PEG-DMG and / or PEG-DSPE, specifically PEG2000-DMG and / or PEG2000-DSPE.

[0303] In some embodiments, the molar ratio of the ionizable sterol compound, phospholipid and polymer-conjugated lipid is 15-70:5-25:0.5-5, or 30-60:5-40:1-5, or 40-60:5-40:1-2.

[0304] III. Lipid Nanoparticle Composition and Preparation Thereof

[0305] This disclosure also provides a lipid nanoparticle composition comprising a therapeutic agent and / or a preventive agent, as well as the above.The ionizable sterol compounds disclosed herein.

[0306] This disclosure further provides a lipid nanoparticle composition comprising a therapeutic agent and / or a preventive agent, and a pharmaceutically acceptable carrier comprising a lipid carrier composition or bioactive substance delivery system as defined herein.

[0307] In some embodiments, the therapeutic agent and / or preventive agent is selected from nucleic acids, peptides, proteins, and small molecule compounds, preferably nucleic acids, which are embedded in a lipid layer or encapsulated in the lumen of lipid vesicles.

[0308] For the lipid nanoparticle composition disclosed herein, the nucleic acid contained herein is selected from one or more of short interfering RNA (siRNA), microRNA (miRNA), pri-miRNA, messenger RNA (mRNA), single guide RNA (sgRNA), CRISPR-RNA (crRNA), trans-activated RNA (tracrRNA), antisense RNA, asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecules, small hairpin RNA (shRNA), plasmid DNA (pDNA), transfer RNA (tRNA), antisense oligonucleotide (ASO), guide RNA, Dicer-substrate RNA (dsRNA), double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), single-stranded RNA (ssRNA), double-stranded RNA (dsRNA), and ribozymes.

[0309] Specifically, the nucleic acid is selected from spontaneous RNA (mRNA), short interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecules, microRNA (miRNA), antisense RNA, ribozymes, Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), and mixtures thereof; preferably, the nucleic acid is RNA, and the RNA is selected from one or more of siRNA, aiRNA, miRNA, dsRNA, shRNA, or mRNA. Specification 32 / 41 pages 45 CN 121378377 A

[0310] In the lipid nanoparticle composition disclosed herein, the types and composition of the lipid components forming the lipid nanoparticles are as generally or specifically defined above.

[0311] In some embodiments, the lipid nanoparticle compositions of this disclosure comprise mRNA and any one of the ionizable sterol compounds defined above, such as phospholipids selected from DSPC, DOPE, or combinations thereof, cholesterol, and PEG-DMG and / or PEG-DSPE, specifically PEG2000-DMG and / or PEG2000-DSPE. The molar ratio of the ionizable sterol compound, phospholipid, structural lipid, and polymer-conjugated lipid is 15–70:0–30:20–60:0.5–10, for example 30–60:5–20:25–50:1–5, 40–60:5–15:30–50:1–2, for example 50:10:38.5:1.5.

[0312] For the lipid nanoparticle compositions of the present disclosure, the N / P ratio of the lipid carrier composition to the nucleic acid is 3–12, for example 3–10, 4–10, 6–10, 6–8, 3–8, 3–6, for example 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, preferably 4–8.

[0313] The amount of therapeutic and / or preventive agents in the lipid nanoparticle compositions of the present disclosure may depend on the size, composition, desired target and / or application or other properties of the nanoparticle composition and the nature of the therapeutic and / or / or therapeutic agent. For example, the amount of RNA that can be used in the lipid nanoparticle composition may depend on the size, sequence and other characteristics of the RNA. The relative amounts of therapeutic and / or preventative agents and other elements (e.g., lipids) in the lipid nanoparticle composition may also vary as appropriate.

[0314] In some embodiments, the ratio (mass / mass ratio) of lipids to therapeutic and / or preventative agents (e.g., the ratio of lipids to mRNA) is from about 10:1 to about 30:1, preferably from 12.5:1 to 25:1, and more preferably from about 15:1.

[0315] The lipid nanoparticle compositions of this disclosure can be characterized by a variety of methods. For example, microscopy (e.g., transmission electron microscopy or scanning electron microscopy) can be used to examine the morphology and size distribution of the lipid nanoparticle compositions. Dynamic light scattering or potentiometry (e.g., potentiometric titration) can be used to measure zeta potential and can also be used to determine particle size.

[0316] In some embodiments, the average particle size of the lipid nanoparticle composition of this disclosure is 50 nm–200 nm, for example 100 nm–200 nm, 170 nm–200 nm, 170 nm–190 nm, for example 50 nm, 100 nm, 150 nm, 160 nm, 170 nm, 175 nm, 180 nm, 185 nm, 190 nm, 195 nm, 196 nm, 197 nm, etc.

[0317] The lipid nanoparticle composition of this disclosure is relatively homogeneous. The polydispersity index (PDI) can be used to represent the uniformity of the particles, i.e., the particle size distribution of the lipid nanoparticle composition. A smaller (e.g., less than 0.3) polydispersity index generally indicates a narrower particle size distribution. The polydispersity index of the lipid nanoparticle composition disclosed herein is 0.1-0.3, for example 0.15-0.3, 0.15-0.25, 0.15-0.2, and can be, for example, 0.1, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.25, etc.

[0318] The lipid nanoparticle composition of this disclosure has an encapsulation rate of at least 50% for therapeutic agents and / or preventive agents such as nucleic acids, for example 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the encapsulation rate may be at least 80%. In some embodiments, the encapsulation rate may be at least 90%, or close to 100%.

[0319] In some embodiments, in the lipid nanoparticle composition of this disclosure,

[0320] the encapsulation rate of the therapeutic agent is ≥50%; or ≥80%; or ≥90%; and / or

[0321] the average particle size of the lipid nanoparticles is 100nm-200nm; and / or

[0322] the dispersibility index of the nanoparticle composition is 0.1-0.3.

[0323] The lipid nanoparticle compositions of this disclosure exhibit excellent stability in terms of average particle size and encapsulation efficiency. After being stored at 4°C for different times in an aqueous medium such as 100 mM Tris-HCl, they show the highest encapsulation efficiency and the smallest particle size change compared to paper nanoparticle compositions prepared from other commonly used ionizable cationic lipid compounds, as shown in the examples below.

[0324] The lipid nanoparticle compositions of this disclosure may also contain one or more permeability enhancer molecules, carbohydrates, biodegradable or biocompatible polymers, surface modifiers, and any substances useful in pharmaceutical compositions, such as one or more pharmaceutically acceptable excipients or auxiliary ingredients, such as, but not limited to, one or more solvents, dispersion media, diluents, dispersants, suspending agents, granulation aids, disintegrants, fillers, flow aids, liquid carriers, binders, surfactants, isotonic agents, thickeners or emulsifiers, buffers, lubricants, oils, preservatives, and other substances.

[0325] In some embodiments, one or more excipients or auxiliary components may constitute more than 50% by mass or volume of the total lipid nanoparticle composition, for example, 60%, 70%, 80%, 90% or more.

[0326] This disclosure also provides a method for preparing the lipid nanoparticle composition, comprising preparing a mixed lipid solution by solvents in an organic solvent at the molar ratio defined herein, with the lipid molecules as defined herein as an oil phase and an aqueous solution of the drug to be delivered, such as mRNA, as an aqueous phase, mixing the oil and aqueous phases, and preparing lipid nanoparticles by methods including but not limited to spray drying, solvent extraction, phase separation, nanoprecipitation, single or double emulsion solvent evaporation, microfluidics, coagulation and other methods well known in the art.

[0327] In some embodiments, a microfluidic preparation system is used to prepare an alcoholic solution of the lipid carrier composition of this disclosure.For example, lipid nanoparticles are prepared by reacting an ethanol solution with an aqueous solution of the nucleic acid, wherein the flow rate ratio (FRR) of the ethanol solution and the aqueous solution in the microfluidic system is 1:2 to 5, preferably 1:3, and the total flow rate is 12 ml / min to 20 ml / min.

[0328] IV. Pharmaceutical Compositions and Formulations

[0329] The lipid nanoparticle compositions of this disclosure can be formulated, in whole or in part, as pharmaceutical compositions or formulations. The pharmaceutical compositions or formulations may contain one or more lipid nanoparticle components. For example, the pharmaceutical compositions or formulations may include one or more lipid nanoparticle compositions containing one or more different therapeutic and / or preventive agents. The pharmaceutical compositions or formulations may further contain one or more pharmaceutically acceptable excipients or adjuvants compatible with one or more components of the nanoparticle composition, such as those excipients or adjuvants described herein with respect to lipid nanoparticle compositions and their content ranges.

[0330] The pharmaceutical compositions or formulations of this disclosure comprising one or more lipid nanoparticle compositions may be prepared by any method known in the pharmaceutical field or hereafter developed, and may be prepared in a variety of forms suitable for a variety of routes and methods of administration. For example, pharmaceutical compositions or formulations may be administered via injection, oral, subcutaneous, inhalation, etc., and may be in liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and pharmaceutical preparations), injectable forms, solid dosage forms (e.g., capsules, tablets, pills, films, powders, and granules), topical and / or transdermal dosage forms (e.g., ointments, creams, pastes, lotions, gels, powders, solutions, sprays, inhalers, patches, suppositories, or drops), suspensions, powders, and other forms. Various formulations may accordingly contain excipients or adjuvants conventional in the art.

[0331] The lipid nanoparticle compositions of this disclosure and / or pharmaceutical compositions or formulations comprising one or more of the lipid nanoparticle compositions may be administered to any patient or subject, including those who may benefit from therapeutic effects provided by delivery of therapeutic and / or preventative agents to one or more specific cells, tissues, organs, or systems or groups thereof (e.g., the renal system). The subjects or patients include humans and any other mammals, cattle, pigs, calves, sheep, cats, dogs, mice and / or rats.

[0332] V. Uses and Methods

[0333] In one aspect, this disclosure provides ionizable sterol compounds or stereoisomers thereof, pharmaceutically acceptable salts or solvates, lipid carrier compositions, lipid nanoparticle compositions, pharmaceutical compositions or formulations for delivering therapeutic and / or preventive agents to mammalian cells, tissues or organs, for generating target peptides in mammalian cells, for treating diseases or conditions in individuals such as mammals such as humans, or for specifically delivering therapeutic and / or preventive agents.

[0334] On the other hand, this disclosure provides the use of the ionizable sterol compounds of this disclosure or their stereoisomers, pharmaceutically acceptable salts or solvates in the preparation of lipid carrier compositions, lipid nanoparticle compositions or pharmaceutical compositions or formulations comprising said lipid nanoparticle compositions.

[0335] On the other hand, this disclosure provides the use of the lipid carrier compositions of this disclosure in the preparation of lipid nanoparticle compositions or pharmaceutical compositions or formulations comprising said lipid nanoparticle compositions.

[0336] On the other hand, this disclosure provides methods for delivering therapeutic agents and / or preventive agents to mammalian cells, tissues or organs, methods for generating target polypeptides in mammalian cells, methods for treating diseases or conditions in mammals such as humans, or methods for specifically delivering therapeutic agents and / or preventive agents to patients, including administering the lipid nanoparticle compositions of this disclosure or pharmaceutical compositions or formulations comprising said lipid nanoparticle compositions to said mammals or patients.

[0337] On the other hand, this disclosure provides the use of the paper nanoparticle compositions or pharmaceutical compositions of this disclosure in the preparation of products for delivering therapeutic and / or preventive agents to mammalian cells, tissues or organs, in the preparation of products for generating target peptides in mammalian cells, in the preparation of medicaments for treating diseases or conditions in individuals such as mammals such as humans, or in the preparation of medicaments for specifically delivering therapeutic and / or preventive agents to individuals.

[0338] In some embodiments, the lipid nanoparticle compositions of this disclosure can be used for treatment. For example, the mRNA contained in the nanoparticle composition can encode a therapeutic peptide (e.g., in a translatable region) and generate the therapeutic peptide upon contact with and / or entry into (e.g., transfection) cells. In other embodiments, the mRNA contained in the nanoparticle composition can encode a peptide that can improve or increase the immunity of a subject.

[0339] For the uses and methods of this disclosure, the therapeutic and / or preventive agents are as defined above, preferably nucleic acids as defined above, more preferably natural or modified mRNAs.

[0340] In some embodiments, the lipid nanoparticle compositions or pharmaceutical compositions or formulations of this disclosure can target specific types or classes of cells (e.g., cells of a specific organ or system). For example, lipid nanoparticle compositions comprising targeted therapeutic and / or preventative agents can be specifically delivered to the liver, kidney, spleen, femur, gastrointestinal tract, eye, or lung of mammals, as well as tumor tissue (e.g., via intratumoral injection). In some embodiments, the nanoparticle compositions can target hepatocytes. In some embodiments, the nanoparticle compositions can target extrahepatic cells. In some preferred embodiments, the nanoparticle compositions can target the spleen, stomach, or intestine.

[0341] For the uses and methods of this disclosure, the disease or ailment is characterized by, for example, protein or peptide activity.The dysfunction or abnormality is selected from pathogen infection, tumor, allergy, autoimmune disease, genetic disease, diabetes, neurodegenerative disease, cardiovascular disease, renal vascular disease or metabolic disease.

[0342] For the use and methods of this disclosure, the lipid nanoparticle composition or pharmaceutical composition or preparation therein can be administered by any route, including oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intravenous, percutaneous or intradermal, intradermal, rectal, intravaginal, intraperitoneal, intraocular, subretinal, intravitreal, local (e.g., by powder, ointment, cream, gel, lotion and / or drops), mucosa, nose, cheek, intestine, vitreous body, intratumoral, sublingual, intranasal, etc.

[0343] For the use and methods of this disclosure, a therapeutic and / or prophylactic agent is administered to an individual such as a mammal such as a human at a dose of 0.0001 mg / kg to 10 mg / kg. For example, therapeutic and / or prophylactic (e.g., mRNA) doses of lipid nanoparticle compositions of about 0.001 mg / kg to about 10 mg / kg, about 0.005 mg / kg to about 2.5 mg / kg, about 0.1 mg / kg to about 1 mg / kg, or about 0.05 mg / kg to about 0.25 mg / kg can be administered at suitable dosing frequencies.

[0344] VI. Effects of the Invention

[0345] The ionizable sterol compounds of this disclosure can be used in the preparation of lipid carrier compositions, lipid nanoparticles, and pharmaceutical compositions or formulations. Lipid nanoparticle compositions or pharmaceutical compositions containing the ionizable sterol compounds of this disclosure can encapsulate and deliver therapeutic / prophylactic agents, safely delivering the therapeutic / prophylactic agents to the target site, achieving high expression, and exerting the therapeutic / prophylactic effects. Specifically, the technical solutions disclosed herein can achieve the following technical effects:

[0346] The ionizable sterol compounds disclosed herein can complex nucleic acid molecules to form stable lipid nanoparticle structures;

[0347] The ionizable sterol compounds disclosed herein can carry two or more ionization sites to achieve high membrane charge density, promote the escape of endosomes from the lipid nanoparticle composition, and improve nucleic acid transfection efficiency; they can complex multiple nucleic acid molecules, greatly reduce the proportion of ionizable cations in LNP, thereby reducing carrier toxicity;

[0348] The ionizable sterol compounds disclosed herein can not only serve as important lipid components for forming lipid nanoparticles, but also, in some embodiments, the ionizable sterol compounds themselves have potent cancer cell differentiation and anti-cancer effects, and possess tumor inhibition, chemoprevention, and neuroprotective properties. Therefore, the lipid carrier compositions, lipid nanoparticle compositions, or pharmaceutical compositions disclosed herein are expected to deliver therapeutic agents and / or preventive agents, and have dual effects of tumor inhibition / chemoprevention / neuroprotection, providing a better option for targeted therapy and gene therapy.

[0349] The sterol compounds disclosed herein contain both ionizable cationic lipid components and sterol components, thus they can act as both ionizable lipids and structural lipids, thereby enabling the realization of a three-component lipid carrier composition or bioactive substance delivery system, thereby reducing the production cost of LNPs and facilitating clinical translation;

[0350] The lipid nanoparticles disclosed herein have small particle sizes, all within 200 nm. Such particle size can avoid in vivo clearance, prolong the circulation time of drugs in vivo, help avoid early drug clearance, and improve the efficiency of targeted drug delivery; and the smaller nanoparticles facilitate sterilization during the preparation process and can more easily pass through microporous filters or microporous membranes;

[0351] The lipid nanoparticles disclosed herein have a low dispersibility index, indicating a uniform particle size distribution, narrow size distribution, and small particle size difference, ensuring stable dispersion during application;

[0352] The lipid nanoparticles disclosed herein have high encapsulation efficiency, and the stability of particle size and encapsulation efficiency is superior to that of lipid nanoparticles prepared from other conventional cationic lipids.

[0353] The various embodiments described in this disclosure (including the embodiments below) and the features of each embodiment should be understood as being arbitrarily combined with each other, and all such combinations are included within the scope of this application, just as these combinations are specifically and individually listed herein, unless the context clearly indicates otherwise.

[0354] Embodiments

[0355] The following embodiments are illustrative of this disclosure and are not intended to limit this disclosure in any way. The data given (such as quantities, temperatures, etc.) are intended to be accurate, but those skilled in the art should understand that some experimental errors and biases may occur. Unless otherwise stated, all temperatures are in degrees Celsius and pressures are at or near atmospheric pressure. Specification page 36 / 41 49 CN 121378377 A

[0356] The mass spectrometry data in this application were obtained by a mass spectrometer (Waters SYNAPT XS); the nuclear magnetic resonance data were obtained by a nuclear magnetic resonance spectrometer (Bruker, AVANCE NEO 400M); the purification operation was performed using a preparative reversed-phase high-performance liquid chromatograph (HS-D-5800D); the LNP was prepared using a refrigerated centrifuge (Beckman); the structure and performance characterization of the LNP were performed using a dynamic light scattering spectrometer (Malvern ZetaSizer), a transmission electron microscope (Hitachi, HT7800), a high-content cell imaging system (PerkinElmer), and a Spark multi-functional microplate reader (TECAN).

[0357] Unless otherwise stated, all reagents and raw materials used in this disclosure are commercially available.

[0358] In any structural formula of this application, if any atom has a vacant valence, the vacant valence is actually a hydrogen atom that is not specifically shown for simplicity.

[0359] List of abbreviations used in the following examples:

[0360] Specification 37 / 41 pages 50 CN 121378377 A

[0361]

[0362] Example 1: Synthesis and characterization of ionizable sterol compounds

[0363] Step 1

[0364]

[0365] Cholesterol (1, Anage / QJDHREAR) (1.0 g, 2.59 mmol, 1.00 equiv) was dissolved in dichloromethane (10.0 mL), and a solution of mCPBA dissolved in dichloromethane (5.0 mL) was added dropwise. The mixture was stirred at room temperature for 3 hours, washed with 10% sodium sulfite aqueous solution and 5% sodium bicarbonate aqueous solution, respectively. The organic phase was dried with anhydrous sodium sulfate and rotary evaporated. The following product, (3S,5aS,6bS,9R,9aR,11aS,11bR-9a,11b)-dimethyl-9-(R)-6-methylheptane-2-yl)hexadecylcyclopentane[1,2]phenanthrene[8a,9-b]oxacycloen-3-ol (2) (2.18 g, crude product, white oily solid), was obtained and used directly in the next reaction. MS (ESI, m / z): 403(M+H)+.

[0366] Step 2

[0367]

[0368] Take (3S,5aS,6bS,9R,9aR,11aS,11bR-9a,11b)-dimethyl-9-(R)-6-methylheptane-2-yl) Specification 38 / 41 pages 51 CN 121378377 A Hexadecylhydrocyclopentane[1,2]phenanthrene[8a,9-b]oxacycloene-3-ol (2) (2.1g, 5.22mol, 1 0.00 equiv), histamine (Maclean / C14228571) (1.2 g, 10.44 mol, 2.00 equiv), and isobutanol (25.0 mL) were refluxed and stirred at 120 °C for 16 hours. After cooling to room temperature, the mixture was rotary evaporated and purified by reverse preparative chromatography (acetonitrile in water (0.5‰ ammonium bicarbonate), 5%–90%) to obtain ST-001 (DDA) (0.7 g, brownish-yellow solid, yield 25%). Mass spectrometry results are shown in Figure 1A, and NMR results are shown in Figure 1B. MS (ESI, m / z): 514 (M+H)+. H NMR (500MHz, DMSO-d6) δ 11.76 (s, 1H), 7.48 (s, 1H), 4.18 (s, 1H), 3.88-3.77 (M, 1H), 3.65 (s, 1H), 2.81-2.69 (m, 1H) ,2.61‑2.51(m ,3H) ,2.28(s ,1H) ,1 .97‑1 .79(m ,3H) , 1.79‑1.71(m,1H) ,1.61‑1.55(m,2H) ,1.55‑1.39(m,7H),1.38-1.22(m, 11H) ,1.21-1.02(m, 13H) ,0.97(d ,J=12.5Hz, 6H) ,0.88(d ,J=6.5Hz, 4H) ,0.84(dd ,J=6.5, 2.5Hz, 8H) ,0.61 (s, 3H) .

[0370] In a similar manner, the ionizable sterol compounds 1-8 of this disclosure were also prepared using the specific sterol fragments available above as described in this disclosure.

[0371] Example 2: Preparation of LNPs

[0372] Using ALC-0315, Dlin-MC3-DMA, SM102, and ST-001 as lipids, lipid nanoparticles (LNPs) encapsulating mRNA were prepared as follows, and were designated as LNP1 (containing ALC-0315), LNP2 (containing Dlin-MC3-DMA), LNP3 (containing SM102), and LNP4 (containing ST-001), respectively.

[0373] 2.1 Preparation of lipid mixtures

[0374] According to the proportions in Table 1 below, each lipid (ST-001 was prepared as described in Example 1, and the remaining lipids were purchased from Aivito Technology Co., Ltd.) was dissolved in ethanol and thoroughly mixed until clear, and stored at 4°C for later use (lipid phase). The total concentration of all components was prepared to be 12 mM (approximately 7.5 mg / ml).

[0375] Table 1 Components and molecular weights of lipid nanoparticles (LNP)

[0376]

[0377]

[0378] 2.2 mRNA preparation

[0379] In this experiment, eGFP-mRNA was used as the model mRNA to prepare LNP and evaluate the transfection efficiency, but the present invention is not limited to specific mRNAs.

[0380] In this experiment, only the nitrogen-phosphorus ratio (N / P) was used to set the amount of mRNA fed. When calculating the nitrogen-phosphorus ratio, only the number of nitrogen atoms in the ionizable lipid was calculated. In this experiment, each mole of mixed lipid contained 0.5 moles of N, and the N / P ratio was 8. Specification 39 / 41 pages 52 CN 121378377 A

[0381] The average molecular weight of RNA bases is 324, and each base carries 1 phosphate, so the phosphorus content in RNA is 3.03 nmol / μg. The mass of mRNA that can be carried per mM of total lipids can be calculated using the following formula:

[0382]

[0383] Based on a lipid concentration of 12 mM, N / P = 8, and FRR = 3, the required RNA concentration is calculated to be 0.081 μg / μl.

[0384] 50 ml of each of 100 mM citric acid monohydrate (C6H8O7·H2O / MW 210.14, 1.05 g) and sodium citrate dihydrate (C6H5Na3O7·2H2O / MW 294.10, 1.47 g) solutions were prepared using ultrapure water. 33.0 ml of citric acid solution and17.0 ml sodium citrate solution was mixed and DEPC was added. After standing for 30 minutes, the mixture was autoclaved to remove DEPC. After sterilization, the volume was adjusted to 100 ml with DEPC-water (purchased from Solarbio) to obtain 50 mM citrate buffer with pH=4. The concentration of mRNA was determined and diluted to the required concentration (aqueous phase) with citrate buffer according to the lipid concentration.

[0385] 2.3 Microfluidic mixing preparation of LNP

[0386] The lipid ethanol solution and aqueous mRNA-citrate buffer were purified by filtration through a 0.22 μm filter membrane. The flow rates of the aqueous and lipid phases were controlled (FRR=3, lipid phase flow rate 4.5 mL / min / aqueous phase flow rate 13.5 mL / min). The mRNA and lipid mixture was loaded into a microfluidic device (Suzhou Zhongxin Qiheng standard micro-mixing liposome chip) at a total flow rate of 15 mL / min. After the flow rate of the outflow tube stabilized, the outflowing liquid was collected with a collection tube to obtain the mRNA loaded with LNP.

[0387] 2.4 Dialysis and Storage

[0388] The LNPs obtained above were placed in a dialysis tube (Slide-A-Lyzer™ Minidialysis Device, 10K MWCO, 0.5mL), and 14mL of PBS (pH 7.4) was added. Dialysis was performed on a shaker, with the medium changed every 2 hours. The operation was repeated until dialysis was completed after 18 hours. Finally, the LNPs were concentrated to an mRNA concentration of 100μg / mL to 200μg / mL. The collected LNPs were stored in PBS (pH 7.4) containing 2% sucrose and frozen at -80℃.

[0389] Example 3: Characterization of the structure and performance of LNPs

[0390] 3.1 Particle size, uniformity and encapsulation efficiency

[0391] The particle size and uniformity of each LNP obtained in Example 2 were determined using a dynamic light scattering instrument or a transmission electron microscope (TEM).

[0392] The Quant-iT™ RNA kit (Thermo Fisher, catalog number R11490) was used, with 1% Triton-100 (SIGMA-ALDRICH, T8787-100ML) as the demulsifier and CellCarrier-96 Ultra Microplates (PerkinElmer, 6055308) was used to determine the obtained LNP-mRNA. The total mRNA content and free content in LNP were detected. The fluorescence intensity (excitation light 480nm, emission light 520nm) was read using a SPARK multi-microplate reader (TECAN), and the encapsulation efficiency was calculated using the following formula:

[0393] Encapsulation efficiency (%) = (quantitative after demulsification - quantitative before demulsification) / quantitative after demulsification

[0394] The results are shown in Figure 2A and Figure 2B and Table 2 below:

[0395] Table 2 Particle size, uniformity and encapsulation efficiency of each LNP

[0396] LNP encapsulation efficiency Particle size (nm)PDI LNP1 95.8% 179.8 0.213 LNP2 95.2% 177.0 0.194 LNP3 97.9% 189.7 0.187 LNP4 98.1% 175.1 0.194

[0397] 3.2 Stability

[0398] The prepared LNPs were placed in an aqueous phase (100mM Tris-HCl) and stored at 4℃ for different periods of time, and continuously monitored for 2 months. Dynamic light scattering (DLS) and transmission electron microscopy (TEM) observations showed that the particle stability of each LNP was good. LNP4 (ST-001), which contained a novel steroidal ionizable lipid, had the highest encapsulation rate and the hydrated particle size changed little within 30 days, indicating that the particle stability was the best. The results are shown in Figure 3.

[0399] Transmission electron microscopy (TEM) observations also showed that the freshly prepared LNPs and the LNPs stored at 4°C (medium: 100mM Tris-HCl) for 30 days exhibited good morphological stability, with only a few fusions or enlargements observed. The results are shown in Figure 4.

[0400] Using the above-mentioned mRNA calculation method, the RNA leakage of the freshly prepared LNPs and the LNPs stored at 4°C (100mM Tris-HCl) for different time periods was also investigated by gel electrophoresis. The results showed that the RNA leakage rate increased with the storage of LNPs. LNP4 (ST-001), which contains novel steroidal ionizable lipids, had the highest encapsulation rate and the least leakage. Within 60 days of storage, the RNA leakage rate changed from 3% to 9%, and the encapsulation rate and stability were superior to other

[0401] LNPs. The results are shown in Figure 5.

[0402] 3.3 Evaluation of LNP transfection efficiency

[0403] Taking mouse mononuclear macrophage leukemia cells RAW264.7 (Wuhan Pronosei Biotechnology Co., Ltd.) as an example, the prepared LNPs encapsulating eGFP-mRNA were used to transfect the cells.

[0404] The cells were plated into 24-well cell culture plates at a cell density of 2.5×104 cells / ml, 1ml / well, and incubated overnight at 36℃. The eGFP-mRNA LNP (50μg / ml) was diluted to 2.5μg / mL with culture medium, and 250μl of LNP transfection solution was added to each well. Each LNP was transfected into 3 wells. After incubation at 36℃ for 4, 6, 8, 12, 24, and 48 hours, the expression of green fluorescent protein (GFP) was observed using a fluorescence microscope (Olympus BX43). Cells were collected after 48 hours, and the GFP signal positivity rate was detected by flow cytometry (Beckman Coulter CytoFLEX). GFP expression gradually appeared after 4 hours, and obvious green fluorescence was visible after 8 hours.

[0405] The results showed that each LNP achieved transfection to varying degrees. The results are shown in Figure 6, indicating that LNP4 (ST-001) had a higher transfection efficiency than the other groups. [Instructions for Use, Page 41 / 41, 54, CN 121378377 A, Figure 1A, Figure 1B, Appendix 1 / 5, Page 55, CN 121378377 A, Figure 2A, Appendix 2 / 5, Page 56, CN 121378377 A, Figure 2B, Figure 3, Appendix 3 / 5, Page 57, CN 121378377 A, Figure 4, Figure 5, Appendix 4 / 5, Page 58, CN 121378377 A, Figure 6, Appendix 5 / 5, Page 59, CN 121378377 A] Abstract: The present disclosure relates to an ionizable sterol compound of formula A, a lipid nanoparticle composition containing the same, and the pharmaceutical use thereof. ZL-(M)r A

Claims

1. An ionizable sterol compound of Formula A, or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, Z-L-(M)r Formula A wherein: Z is a structure described by Formula B below, wherein the wavy line indicates the point of attachment to L; R 1a is H, C 1-6 alkyl, -C(O)NR a R b , -C(O)R c , -C(O)OR d , or an amino acid residue wherein R e is selected from the residue moiety of L-histidine, L-leucine, L-isoleucine, L-valine, L-phenylalanine, L-tryptophan, L-lysine, L-tyrosine; wherein R a and R b are the same or different from each other and are selected from the group consisting of H, -C 1-6 alkyl, -C 2-6 alkenyl and -C 2-6 alkynyl, each optionally substituted with one or more groups selected from the group consisting of allyl, carbonyl and 5- to 10-membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, S, R c and R d each independently is -C 1-6 alkyl, -C 2-6 alkenyl or -C 2-6 alkynyl; R 1b is H, -C 1-6 alkyl, -C 2-6 alkenyl or -C 2-6 alkynyl; R2is H, OH, or -OC 1-6 alkyl; R3 is H or CH3; W is selected from N and CR when W is a single bond to the carbon atom at the adjacent * position f R4 is H or OH; W is C when W is a double bond to the carbon atom at the adjacent * position, R4 is absent; R f is absent, H, halogen, or -C 1-6 alkyl; R 5a and R 5b each independently is H, OH, or -OC 1-6 alkyl, or R 5a and R 5b together with the ring carbon atom to which they are attached form -C(O)-; L is a linking unit which is an optionally substituted straight chain or branched alkylene having 3-50 skeletal carbon atoms, covalently linking the steroid ring fragment and r ionizable head groups M, wherein at least 1 skeletal carbon atom of L is replaced by -0-, -S-, -NR6-, -NR6-NR6', -N=N-, -CH=N-, -N=CH-, -CH=CH-, -CºC-, -0-NR6-, -S-S-, -SO-, -S02, -C(O)-, -C(=S)-, -C(=NR6)-, -C(0)0-, -C(0)S-, -OC(O)-, -SC(O)-, -NR6C(0)-, -C(0)NR6-, -NR6S02-, -S02NR6-, -OC(0)0-, -NR6C(0)0-, -OC(0)NR6-, -SC(0)NR6-, -NR6C(0)NR6'-, -NR6C(0)S-, -P(0)(OR6)0-, -OP(0)(OR6)-, -OP(0)(OR6)0-, optionally substituted C 3-8 cycloalkylene, optionally substituted 3-8 membered heterocyclylene, optionally substituted C 6-10 arylene, or optionally substituted 5-10 membered heteroarylene; wherein each R6and R6' is independently H, optionally substituted -C 1-12 alkyl or optionally substituted -C 2-12 alkenyl; M is -(CH2) p M1is selected from NR7R8, an optionally substituted saturated or partially unsaturated 3-8 membered heterocyclyl containing at least one nitrogen atom, and an optionally substituted 5-10 membered heteroaryl containing at least one nitrogen atom; R7and R8are each independently selected from H, optionally substituted -C 1-6 alkyl, optionally substituted -C 2-6 alkenyl, optionally substituted -C 2-6 alkynyl; G1is either nothing, or G2 is absent, or is G3 is absent, or is R 11a and R 11b each independently is H, -OH, or C 1-6 alkyl; R 12 selected from -C 3-10 alkyl, -C 3-10 alkenyl, -C 3-10 cycloalkyl, -C 3-10 cycloalkenyl, -C 6-10 aryl, -3-8 membered heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from N, O, S, -5-10 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, S, halogen, -OH, -OC 3-10 alkyl, -NR 13a R 13b wherein each of said cycloalkyl, aryl, heterocyclyl, and heteroaryl is optionally substituted with -C 1-6 alkyl; R 13a and R 13b each independently is H or -C 1-6 alkyl; p is an integer from 0 to 6; and q and r are each independently an integer from 1 to 3.

2. The ionizable sterol compound according to claim 1, or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, having the following formula, wherein: L1and L2are each independently absent or straight-chain or branched -C 1-12 alkylene-, wherein alkylene is optionally substituted with OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), -OC 1-6 alkyl, -C 1-6 alkyl, -C 2-6 alkenyl, -C 3-8 cycloalkyl, and wherein alkylene is optionally interrupted with one or more -O-, -S-, -NR6-, -CH=CH-, -CºC-, -C(O)-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6-, -OC(O)NR6- or -OC(O)O-; X is selected from the group consisting of absent, -0-, -S-, -NR6-, -NR6-NR6'-, -N=N-, -CH=N-, -N=CH-, -CH=CH-, -CºC-, -0-NR6-, -S-S-, -SO-, -S02, -C(O)-, -C(=S)-, -C(=NR6)-, -C(0)0-, -C(0)S-, -OC(O)-, -SC(O)-, -NR6C(0)-, -C(0)NR6-, -NR6S02-, -S02NR6-, -OC(0)0-, -NR6C(0)0-, -OC(0)NR6-, -SC(0)NR6-, -NR6C(0)NR6'-, -NR6C(0)S-, -P(0)(OR6)0-, -OP(0)(OR6)-, -OP(0)(OR6)0-, optionally substituted C 3-8 cycloalkylene, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 6-10 aryl or optionally substituted 5-10 membered heteroaryl, wherein the optional substituents are selected from the group consisting of -OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(0)N(R6R6'), -OC 1-6 alkyl, -C 1-6 alkyl, -C 2-6 alkenyl, -C 3-8 cycloalkyl; R6and R6' are each independently H, -C 1-12 alkyl or -C 2-12 alkenyl, each optionally substituted with -OH, -COC 1-6 alkyl, -COOC 1-6 alkyl, -NH2, -NHC 1-6 alkyl, -N(C 1-6 alkyl)2, oxo, halogen, cyano, nitro, -C(O)NH2, -C(O)NHC 1-6 alkyl, -C(O)N(C 1-6 alkyl)2, -OC 1-6 alkyl, -C 1-6 alkyl, -C 2-6 alkenyl, -C 3-8 cycloalkyl; M is -(CH2) p -M1, wherein M1 is selected from NR7R8, a saturated or partially unsaturated 3-8 membered heterocyclic group containing at least one nitrogen atom, or a 5-10 membered heteroaryl group containing at least one nitrogen atom, wherein the heterocyclic group or heteroaryl group is optionally surrounded by one or more OH groups, -COR6, -COOR6, -NR6R6', oxo groups, halogens, cyano groups, nitro groups, -C(O)N(R6R6'), amido groups, guanidino groups, or -OC groups. 1-6 Alkyl and -C 1-6 Alkyl substitution; R7and R8are each independently selected from H, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, each optionally substituted with one or more groups selected from OH, -COR6, -COOR6, -NR6R6', -C(O)N(R6R6'), amidine, guanidine, halogen, cyano, nitro, -OC 1-6 alkyl, -(OC 1-6 alkylene) n -OH, saturated or partially unsaturated 3-8 membered heterocyclyl containing at least one nitrogen atom, 5-10 membered heteroaryl containing at least one nitrogen atom, wherein the heterocyclyl or heteroaryl is optionally substituted with one or more OH, -COR6, -COOR6, -NR6R6', oxo, halogen, cyano, nitro, -C(O)N(R6R6'), amidine, guanidine, -OC 1-6 alkyl and -C 1-6 alkyl substituted; n is an integer from 1 to 4.

3. The ionizable sterol compound according to claim 1 or 2, a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, which is 4. The ionizable sterol compound, stereoisomer, pharmaceutically acceptable salt, or solvate thereof, according to any one of claims 1 to 3, wherein R 1a is selected from H, -C 1-6 alkyl and -C(O)C 1-6 alkyl.

5. The ionizable sterol compound, stereoisomer, pharmaceutically acceptable salt, or solvate thereof, according to any one of claims 1 to 2, wherein R 1b is H.

6. The ionizable sterol compound according to any one of claims 1 to 2, a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R2 is H.

7. The ionizable sterol compound according to any one of claims 1 to 6, a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R3 is -CH3.

8. The ionizable sterol compound according to any one of claims 1 to 7, a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein there is a single bond between W and the * carbon atom, W is CH, and R4 is OH.

9. An ionizable sterol compound, stereoisomer, pharmaceutically acceptable salt, or solvate thereof, according to any one of claims 1, 2, 4 to 8, wherein R 5a and R 5b are each independently H.

10. The ionizable sterol compound according to any one of claims 1 to 9, a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein G1is wherein R 11a and R 11b one is H and the other is C 1-3 alkyl, preferably methyl; G2 is wherein q is 2; G3 is absent; and R 12 selected from -C 3-10 alkyl and -C 3-10 alkenyl, preferably -C 3-6 alkyl and -C 3-6 alkenyl.

11. The ionizable sterol compound, stereoisomer, pharmaceutically acceptable salt, or solvate thereof, according to claim 10, wherein R 12 having the formula: wherein R 12a is selected from H, -CH3, -CH2CH3, =CHCH3.

12. The ionizable sterol compound according to any one of claims 1 to 11, a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is selected from the following fragments: wherein R 1a is H, -C 1-6 alkyl and -C(O)C 1-6 alkyl, preferably H, -C 1-3 alkyl and -C(O)C 1-3 alkyl.

13. The ionizable sterol compound according to any one of claims 2 to 12, a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein L1 is absent; and / or X is selected from -0-, -S-, -NR6-, -NR6-NR6’-, -0-NR6-, -C(O)-, -C(0)0-, -OC(O)-, -NR6C(0)-, -C(0)NR6-, -OC(0)0-, -NR6C(0)0-, -OC(0)NR6-, -NR6C(0)NR6’-; preferably X is selected from -0-, -NR6-, -OC(O)-, -NR6C(0)-, -OC(0)0-, -NR6C(0)0-, -OC(0)NR6-, -NR6C(0)NR6’-; and / or L2is straight-chain or branched -C 1-12 alkylene, optionally substituted with -OH, -NR6R6', halogen, -OC 1-6 alkyl, and optionally interrupted with one or more -O-, -NR6-, -C(O)O-, -OC(O)-, -NR6C(O)-, -C(O)NR6-, -NR6C(O)O-, -NR6C(O)NR6'-, -OC(O)O-, or -OC(O)NR6-; wherein R6and R6' are each independently H, -C 1-6 alkyl or -C 2-6 alkenyl; preferably each independently H or -C 1-6 alkyl, optionally substituted with -OH, -NH2, -NHC 1-6 alkyl, -N(C 1-6 alkyl)2, preferably optionally substituted with -OH.

14. The ionizable sterol compound according to claim 13, a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein: L2comprises the repeating structural fragment -[(CH2) m -O] t - wherein m is an integer from 1 to 6 and t is an integer from 0 to 6; for example m is an integer of 2 and t is an integer from 2 to 6; for example m is an integer from 1 to 6 and t is 1 ; and / or L2comprises the repeating structural fragment -[(CH2) m -NR6] t - wherein m is an integer from 1 to 6 and t is an integer from 0 to 6; for example m is an integer from 2 to 4 and t is an integer from 2 to 6; for example m is an integer from 1 to 6 and t is 1 ; and / or alkylene of L2is interrupted by one or more -NR6C(O)O-, -NR6C(O)NR6'-, -OC(O)NR6-, or -OC(O)O-; for example, -C 1-6 alkylene-O-CO-NR6-C 1-6 alkylene-, -C 1-6 alkylene-O-CO-O-C 1-6 alkylene-, -C 1-6 alkylene-NR6-CO-O-C 1-6 alkylene-, -C 1-6 alkylene-NR6-CO-NR6-C 1-6 alkylene-.

15. The ionizable sterol compound according to any one of claims 1 to 12, a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein the linker L or -L1-X-L2- has the following structure: wherein, the asterisk * indicates the point of attachment to the steroid ring, the wavy line alone indicates the point of attachment to M, multiple wavy lines indicate at least one point of attachment to M and the remaining points of attachment to H or alkyl branches of L2, m is an integer from 1 to 6, and t is an integer from 0 to 6.

16. The ionizable sterol compound, stereoisomer, pharmaceutically acceptable salt, or solvate thereof, according to any one of claims 1 to 15, wherein: M is -(CH2) p -M1, wherein M1is NR7R8, R7and R8are each independently selected from H and optionally substituted -C 1-6 alkyl, wherein the alkyl is optionally substituted with one or more -OH, -COOH, -NR6R6', oxo, halogen, cyano, nitro, or -OC 1-6 alkyl, in particular optionally substituted with one or more -OH and / or -NR6R6'; For example, M is selected from: wherein -C 1-6 alkyl is optionally substituted with -OH.

17. An ionizable sterol compound, stereoisomer, pharmaceutically acceptable salt, or solvate thereof, according to any one of claims 1 to 15, wherein M is -(CH2) p M1, wherein M1 is selected from each optionally substituted by one or more OH, -COOH, -NH2, oxo, halo, cyano, nitro, -OC 1-6 alkyl and C 1-6 alkyl.

18. The ionizable sterol compound, stereoisomer, pharmaceutically acceptable salt, or solvate thereof, according to any one of claims 1 to 17, wherein 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -propionic acid; 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; L-Histidine 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; L-Histidine 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; L-Histidine 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; L-Histidine 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; L-Histidine 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; L-Histidine 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; L-Histidine 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; L-Histidine 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid; L-Histidine 5a-Hydroxy-6 -[2-(1 H-imidazol-4-yl)-ethylamino]-cholestane-3 -hexanoic acid.

19. A lipid carrier composition comprising the ionizable sterol compound, or stereoisomer, pharmaceutically acceptable salt, or solvate thereof, according to any one of claims 1 to 18, and a phospholipid, a structural lipid, and a polymer-conjugated lipid, preferably in the form of a lipid nanoparticle.

20. The lipid carrier composition according to claim 19, wherein the ionizable sterol compound is present in a molar percentage of about 15% to about 65%, preferably about 30% to about 60%, more preferably about 40% to about 60%, most preferably about 50%, relative to the total lipid.

21. The lipid carrier composition according to claim 19 or 20, wherein the phospholipid is selected from: Dilauroylphosphatidylcholine (DLPC), Dimyristoylphosphatidylcholine (DMPC), Dioleoylphosphatidylcholine (DOPC), Dioleoylphosphatidylcholine (DOPC), Dipalmitoylphosphatidylcholine (DPPC), Distearoylphosphatidylcholine (DSPC), Dioleoylphosphatidylcholine (DUPC), Palmitoyloleoylphosphatidylcholine (POPC), 1,2-Di-O-octadecyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-Oleoyl-2-cholamidemethylsuccinate-sn-glycero-3-phosphocholine (OChemsPC), l-Hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-Divinyl-sn-glycero-3-phosphocholine, 1,2-Diarylacyl-sn-glycero-3-phosphocholine, 1,2-Di-arachidonoyl-sn-glycero-3-phosphocholine, 1,2-Di-docosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-Dioleoyl-SN-glycero-3-phosphoethanolamine (DOPE), 1,2-Diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-Di-arachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-Divinyl-sn-glycero-3-phosphoethanolamine, 1,2-Divinyl-sn-glycero-3-phosphoethanolamine, 1,2-Diaryl-sn-glycero-3-phosphoethanolamine, 1,2-Dithiahexadecanoyl-sn-glycero-3-phosphoethanolamine, 1,2-Di-docosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-Diolyl-sn-glycero-3-phospho-(1-glycerol) sodium salt (DOPG), Dipalmitoylphosphatidylglycerol (DPPG), Palmitoyloleoylphosphatidyethanolamine (POPE), Distearoyl-phosphatidyl-ethanolamine (DSPE), Dipalmitoylphosphatidyethanolamine (DPPE), Dimyristoylphosphoethanolamine (DMPE), 1-Stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), 1-Stearoyl-2-oleoyl-phosphatidylcholine (SOPC), or Sphingomyelin, and mixtures thereof, Preferably the phospholipid is DOPE or DSPC.

22. The lipid vehicle composition according to any one of claims 19 to 21, wherein the phospholipid is present in a molar percentage of the total lipids of about 0% to about 30%, preferably about 5% to about 20%, more preferably about 5% to about 15%, most preferably about 10%.

23. The lipid vehicle composition according to any one of claims 19 to 22, wherein the structural lipid is selected from one or more than two of cholesterol, cholestanol, sitosterol, ergosterol, stigmasterol, preferably cholesterol.

24. The lipid vehicle composition according to any one of claims 19 to 23, wherein the structural lipid is present in a molar percentage of the total lipids of about 20% to about 50%, preferably about 25% to about 50%, more preferably about 35% to about 50%.

25. The lipid carrier composition according to any one of claims 19 to 24, wherein the polymer-conjugated lipid is a PEG-modified lipid selected from one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol or PEG-modified dialkylglycerol, preferably selected from 1,2-dimyristoyl-sn-glycero- methoxypolyethyleneglycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine- N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-distearyl glycerol (PEG-DSG), PEG- dipalmitoyl, PEG-dioleoyl, PEG-distearoyl, PEG-diacetylglycamide (PEG-DAG), PEG- dipalmitoyl phosphatidyl ethanolamine (PEG-DPPE) or PEG-l,2-dimyristyloxypropyl-3- amine (PEG-c-DMA), more preferably selected from 1,2-dimyristoyl-sn-glycero-methoxypoly- ethyleneglycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(poly- ethyleneglycol)] (PEG-DSPE).

26. The lipid carrier composition according to any one of claims 19 to 25, wherein the polymer-conjugated lipid is present in a molar percentage of about 1% to about 10% of the total lipid, preferably about 1% to about 5%, more preferably about 1% to about 2%.

27. The lipid carrier composition according to any one of claims 19 to 26, wherein the molar ratio of the ionizable sterol compound, the phospholipid, the structural lipid and the polymer- conjugated lipid is 30-60:5-20:25-50:1-5, preferably 40-60:5-15:30-50:1-2.

28. A lipid nanoparticle composition comprising the lipid carrier composition according to any one of claims 19 to 27, and a therapeutic and / or prophylactic agent selected from the group consisting of nucleic acid molecules, polypeptides, proteins and small molecule compounds, preferably nucleic acids.

29. The lipid nanoparticle composition according to claim 28, wherein the nucleic acid is selected from the group consisting of messenger RNA (mRNA), short interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecules, microRNA (miRNA), antisense RNA, ribozymes, Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA) and mixtures thereof.

30. The lipid nanoparticle composition according to claim 28 or 29, wherein the mass ratio of the lipid carrier composition and the therapeutic or prophylactic agent is 10:1-30:1, preferably 12.5:1-25:1, more preferably 15:1, and / or the N / P (nitrogen to phosphor ratio) of the lipid carrier composition and the nucleic acid is 3-12, preferably 6-10, more preferably 4-8.

31. The lipid nanoparticle composition according to any one of claims 28 to 30, wherein the encapsulation efficiency of the therapeutic agent is > 50%; or > 80%; or > 90%; and / or the average particle size of the lipid nanoparticle is 100-200 nm; and / or the nanoparticle composition has a dispersibility index of 0.1-0.

3.

32. A pharmaceutical composition comprising the lipid nanoparticle composition of any one of claims 28 to 31 and a pharmaceutically acceptable excipient.

33. The ionizable sterol compound of any one of claims 1 to 18, or the lipid carrier composition of any one of claims 19 to 27, for use in delivering a therapeutic and / or prophylactic agent to an individual.

34. The lipid nanoparticle composition of any one of claims 28 to 31 or the pharmaceutical composition of claim 32 for use as a medicament, preferably for treating a disease or condition in an individual.

35. Use of the lipid nanoparticle composition of any one of claims 28 to 31 or the pharmaceutical composition of claim 32 in the manufacture of a medicament for treating or preventing a disease or condition in a mammal, e.g., a human, e.g., the disease or condition is characterized by a dysfunction or abnormality in a protein or polypeptide activity; e.g., the disease or condition is selected from the group consisting of an infectious disease, a cancer and a proliferative disease, a genetic disease, an autoimmune disease, diabetes, a neurodegenerative disease, a cardiovascular disease, a renal vascular disease, or a metabolic disease.

36. The lipid nanoparticle composition of any one of claims 28 to 31 or the pharmaceutical composition of claim 32 for use in treating or preventing a disease or condition in a mammal, e.g., a human, e.g., the disease or condition is characterized by a dysfunction or abnormality in a protein or polypeptide activity; e.g., the disease or condition is selected from the group consisting of an infectious disease, a cancer and a proliferative disease, a genetic disease, an autoimmune disease, diabetes, a neurodegenerative disease, a cardiovascular disease, a renal vascular disease, or a metabolic disease.

37. A method of delivering a therapeutic or prophylactic agent to a mammalian cell or organ, comprising administering to a subject the lipid nanoparticle composition of any one of claims 28 to 31 or the pharmaceutical composition of claim 32, and contacting the cell or organ with the lipid nanoparticle or the pharmaceutical composition comprising the same; preferably the mammal is a human; preferably the lipid nanoparticle or the pharmaceutical composition comprising the same is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

38. A method of treating or preventing a disease or condition in a mammal, e.g., a human, the method comprising administering to the mammal a therapeutically or prophylactically effective amount of the lipid nanoparticle composition of any one of claims 28 to 31 or the pharmaceutical composition of claim 32; e.g., the disease or condition is characterized by a dysfunction or abnormality in a protein or polypeptide activity; e.g., the disease or condition is selected from the group consisting of an infectious disease, a cancer and a proliferative disease, a genetic disease, an autoimmune disease, diabetes, a neurodegenerative disease, a cardiovascular disease, a renal vascular disease, or a metabolic disease; e.g., the nanoparticle composition or the pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.